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ABSTRACT
IMPACT OF DIETARY BIOACTIVE COMPONENTS IN CHRONIC
DISEASES USING NUTRIGENOMICS, NUTRIEPIGENOMICS, AND
METAGENOMICS APPROACHES

BIJAYA PRASAD UPADHYAYA
2016

Chronic diseases that include seven of the top ten leading causes of premature
deaths in the United States demand more than eighty percent of all health care cost.
Although typical Western diets--high fat (HF), low fiber and low vegetables-- are
frequently associated with increased risk for chronic diseases like obesity, metabolic
syndrome (MetS), type 2 diabetes, cardiovascular diseases (CVD), and cancer, there is a
lack of mechanistic understanding of a causal relationship between diet and disease
phenotypes, particularly in a clinical setting. This dissertation research aimed to address
this research gap through the effects of wheat fiber-derived resistant starch type 4 (RS4)
in MetS, maternal HF diet on offspring cardiovascular health, and cruciferous vegetablesderived phenethyl isothiocyanate (PEITC) in cancer prevention, using next generation
“omics” technologies and molecular nutrition approaches.
RS4 flour (30%) enriched differential abundance of 71 bacterial operational
taxonomic units in fecal samples obtained from Hutterite participants having MetS. RS4
not only showed butyrogenic effects in humans but also increased cecal mass and
butyrate concentration in mice, signifying the role of dietary fiber in bowel health.
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Butyrate induced tri-methylated lysine 27 on histone 3 (H3K27me3) in the promoter of
nuclear factor-kappa-B1 (NFκB1) contributing to epigenetic repression of intestinal
inflammation in mice. A genome-wide differential chromatin landscape of histone
modifications (H3Ac, H3K4me3, and H3K27me3) was observed in offspring due to their
maternal HF (40% kcal) diet, implicating the increased risks for obesity, diabetes, and
CVDs beyond one generation. PEITC inhibited cancer stem cell (CSC) marker aldehyde
dehydrogenase 1 (ALDH1) with concomitant induction of oxidative stress and apoptosis
in cervical CSCs, conferring improved therapeutic outcomes in cancer patients.
This dissertation presents a body of translational research work on diet-gene
interaction, which is expected to contribute to the fast-growing nutrigenomics
knowledgebase and inform about (1) diet-responsive gut microbiota and metabolites, (2)
fetal-reprogramming to prevent adult-onset of chronic diseases, and (3) chemo-preventive
strategies to improve therapeutic outcomes of cancer by minimizing recurrence and
metastasis. Together, these findings will contribute to future dietary recommendations
that are expected to be more precise than at current times.

Keywords: Butyrate, Cancer stem cells, Clinical research, Gestational diabetes, Gut
microbiota, High fat diet, Histone modifications, Metabolic syndrome, Phenethyl
isothiocyanate, Preclinical disease model, Resistant starch type 4
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CHAPTER 1 . INTRODUCTION AND DISSERTATION ORGANIZATION
1.1. Nutrigenomics and Nutriepigenomics in Health
Since the time of Hippocrates (460-370 BC) food is considered a medicine in
maintaining health and wellness. The Human Genome Project (1990-2003) followed by
various post-genomic research initiatives along with the advent of modern
biotechnological tools has opened numerous opportunities to establish the validity of
this notion experimentally, and to explain how environmental factors like diet alter the
expression and/or structure of an individual’s genetic makeup. This new era of
molecular nutrition is unfolding in terms of individual response to nutrients due to own
genetic variation (i.e., nutrigenetics), or in terms of the effects of food bioactives on the
regulation of gene expression (i.e., nutrigenomics) [1]. Hence, nutrigenomics is a
discovery science, which aims to understand how diet-gene interactions influences
metabolic and disease pathways, how this regulation is disturbed in the early phase of
diet-related diseases, and how dietary interventions prevent the individuals at risk from
such diseases [2] (Figure 1.1).
Furthermore, nutriepigenomics deals with the elucidation of how biologically
active dietary components modulate the landscape of a gene position in chromatin or
chromosome, without changing the DNA sequence, and regulate the turning “on” and
“off“ the genes epigenetically [3]. However, many common diseases, such as obesity,
cancer, diabetes, and cardiovascular diseases are polygenic in nature, which means that
they arise from the dysfunction in a cascade of genes. Therefore, dietary intervention to
prevent the onset of such diseases is a complex and challenging goal, and requires a
thorough understanding of molecular nutrition, genetics, physiology, pathology,
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biochemistry, bioinformatics, and wide array of “omics” technologies [4]. Powerful
new parallel sequencing technologies have allowed for large scale genomic analysis of
complex microbial populations, once unidentifiable due to inability to culture in vitro.
These metagenomic approaches allow for both qualitative and quantitative microbial
population analysis in both health and diseases.

1.2. Gut Microbiota and Metabolic Diseases
The human gut is colonized by trillions of microorganisms; including hundreds
of different species of bacteria, viruses and fungi that outnumber the host cells by 10
fold [5]. These gut microbiota not only directly associates with the food that we eat [6,
7] but also involve in triggering immune cells underlying a single layer of gut
epithelium. There exists a mutually beneficial association between the resident gut
microbiota and a healthy host [8]. Commensal bacteria co-evolved with their hosts and
hence are not pathogenic under normal or healthy conditions. The dominant residents of
human gut are Gram-negative strict anaerobes, including Bacteriodes, Bifidobacterium,
Fusobacterium, Eubacterium, Peptostreptococcus, and Atopobium [9]. However, under
specific conditions, this ecological homeostasis cannot be maintained, leading to
pathologic imbalance of gut microbiota, termed dysbiosis. Dysbiosis triggers a multitude
of chronic human disease conditions, such as inflammatory bowel diseases (IBD) [10],
intestinal cancers [11], obesity [12], type 2 diabetes [13], atherosclerosis [14], and
alteration of bone metabolism [15]. Hence, the three-way interaction among the diet, gut
microbiota and host play a critical role in shaping intestinal as well as extra-intestinal
health and diseases.
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The microbiota being an essential component in gut microenvironment plays a
critical role in the pathogenesis of intestinal as well as extra-intestinal diseases. As most
of the bacteria reside in the human gut in close proximity to intestinal epithelium, their
composition and metabolism are directly influenced by the foods ingested. Given the
ability to impact on the fine balance between health and disease, it is reasonable to tailor
novel strategies to prevent bowel inflammation and associated comorbidities through
dietary interventions (Figure 1.2).

1.3. Fiber diet, resistant starch and Metabolic Syndrome
While dietary fiber is associated with a lower risk of obesity and cancer [16],
diets high in refined carbohydrates are associated with significant increases in obesity
and metabolic syndrome (MetS) [17]. Based on International Diabetes Federation (IDF)
criteria, MetS is identified with central obesity (≥102 cm in men and ≥88 cm in women)
plus any two of the following four parameters:
1.

Raised blood pressure: systolic BP ≥130 mm Hg or diastolic BP ≥85 mm Hg or
any medication for hypertension,

2.

Raised triglycerides: ≥150 mg/dl (1.7 mmol/l) or history of medication for
triglycerides abnormality,

3.

Reduced high-density lipoprotein (HDL) cholesterol: < 40 mg/dl (1.03 mmol/l)
in males and < 50 mg/dl (1.29 mmol/l) in females or history of medication for
HDL abnormality, and

4.

Raised fasting blood glucose level: ≥ 100 mg/dl or previously diagnosed with
type 2 diabetes mellitus [18].
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Considering a typical Western lifestyle with high-fat and high-carbohydrates in
diets with less physical activity, the chances of acquiring MetS is even higher.
According to American Heart Association and National Health and Nutrition
Examination Survey 1999–2010, almost 34% of American adults are affected by MetS
that multiply a person's risk for heart disease, diabetes and stroke [19].
Prebiotics are non-digestible and selectively fermentable complex
oligosachharides or other ingredients that confer health benefits due to selective changes
in composition or activity of the gut microbiota [20]. Digestive fermentation of complex
carbohydrates and fibers results in the formation of a number of SCFAs, which
positively modulate colonic health through several mechanisms [21].
The major source of carbohydrate in the human diet is starch. There are five
types of RS: physically inaccessible RS1 found in partly milled grains and seeds;
resistant granules RS2 found in raw potato, green banana, some legumes, and highamylose starches; retrograded RS3 found in cooked and cooled potato, bread, and
cornflakes; and chemically modified RS4 as etherized, esterified, or cross-bonded
starches [22] along with a newly reported amylose-lipid complex RS5 (Table 1.1). RS4
resists digestion in the small intestine due to its chemical modification, and passes to the
colon where it is subjected to gut microbiota-mediated fermentation [23]. It has been
shown that dietary interventions with RS4 attenuated various risk factors for metabolic
syndrome (MetS) characterized by several conditions such as insulin-resistance,
dyslipidemia, abdominal obesity, and hypertension that ultimately lead to atherosclerosis
and cardiovascular disease (CVD) [24, 25]. Diets high in resistant starch (RS)
profoundly affect the types of fecal bacteria, including species related to Ruminococcus
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bromii, which can contribute to starch degradation and SCFA production [26]. An
increased consumption of RS produces more butyrate, which is associated with higher
insulin sensitivity and improved glycemic control [27], suggesting the role of gut
microbiota in promoting the host health [24].
RS has certain advantages over other dietary fibers in terms food applications.
For instance, RS has a white, tasteless powder-like texture with a small particle size,
rendering it more desirable for a variety of bakery products, pasta products, cereals, and
snacks, etc. to increase the dietary-fiber contents and improve the quality of the final
products [28]. This forms the basis for objective of chapter 2 to investigate how RS4
modulates gut microbiota and its metabolite SCFAs in individuals with signs of MetS.

1.4. Short-Chain Fatty Acids, Gut Epithelial Integrity and Mucosal Immunity
Gut epithelial cells are tightly packed with paracellular tight-junction proteins
(TJPs) to act as a defensive barrier between luminal microbes and underlying immune
cells. Only some antigen presenting cells (APCs) are well trained to constantly sample the
luminal microbes that distinguish luminal microflora from pathogens, without alarming
mucosal immunity [29]. However, in case of pathogenicity, these APCs recognize the
pathogens based on their pathogen associated molecular pattern and signal to respective
toll-like receptor (TLR) cascades, resulting into inflammation and associated immune
response [30]. Therefore, it is most necessary to maintain the gut barrier function to
control the chronic low-grade inflammation.

A recent study found a strong association between lower fiber intake, and
subsequent lower production of SCFAs with early tumor development in patients at high
risk of CRC [31]. Further, butyrate oxidation is the primary energy source for human
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colonocytes and is strongly anti-inflammatory by inhibiting production of inflammatory
cytokines and inhibition of inflammatory pathways like NFκB activation [21].
SCFA butyrate is the product of bacterial carbohydrates and fiber
polysaccharides fermentation in the human gut [32, 33]. Butyrate has both trophic and
bioactive functions on host cells. Besides correcting the altered ratio of gut bacteria [34],
butyrate can modulate intestinal and colonic inflammation by protecting against the
potential pro-inflammatory molecules due to its ability to modulate gene expression
[35], which could lead to an anti-inflammatory effect and inhibit the progression of lowgrade chronic inflammation. Epigenetically, butyrate has been linked to histone
deacetylase (HDAC) inhibiting properties in several cell lines and is considered to be a
promising treatment for cancer. Butyrate might mitigate low-grade chronic inflammation
by suppressing the transcription of inflammatory genes through H3K27 tri-methylation
[36] or acting as an HDAC inhibitor [37] in colon cancer cells. This serves the basis of
our objective of chapter 3 that dietary RS4 improves the luminal effects of butyrate on
inducing histone modifications (e.g. H3K4Me3) by regulating chemokines (e.g. CCL2)
and transcription factors (e.g. NFκB).

1.5. High-Fat Diet, Gestational Diabetes and Fetal Programming
Stimuli such as over nutrition, physical inactivity, and aging can result in chronic
low-grade inflammation, leading to insulin resistance and diabetes in genetically or
metabolically predisposed individuals [38]. Obesity epidemics is rising world wide [39],
and alarmingly 34.4% of US women are obese in their child-bearing stage [40], resulting
the higher incidence of gestational diabetes mellitus (GDM). GDM is one of the most
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common complications in pregnancy that occurs when high fasting glucose (> 92−125
mg/dL) associated glucose intolerance is first diagnosed at any time of pregnancy, or in
between 24 and 28 weeks in particular [41]. Of note, 17.8% (9.3-25.5%) of overall
pregnancies in the US are affected by GDM [42].
Over nutrition or maternal high fat (HF) diet during the pregnancy is another
critical factor to shape the adult onset of metabolic diseases in the offspring [43, 44]. In
GDM, a food plan focused on controlling carbohydrate often adds up more fat in the diet
[45] in order to meet the caloric needs of a rapidly growing fetus. Since heart constantly
demands a high-energy source to maintain its contractile activity, heart prefers to utilize
all fuel sources including fatty acids [46]. Hence, the quantity as well as quality of the
dietary fat during pregnancy plays a major role in cardiometabolic health outcomes in
offspring above and beyond the pregnant mother [47].
Altogether, the interaction between fetal and maternal environment and
modulation of gene expression that starts very early in life and that can pass across
generations due to epigenetic modifications such as DNA methylation and covalent
posttranslational histone modifications [48]. This forms the rationale of chapter 4 that
maternal HF diet affects streptozotocin (STZ)-induced gestational diabetes to alter the
metabolic programming in the offspring using a neonatal heart tissues in suitable rat
model.

1.6. Phenethyl Isothiocyanate, Cancer-Stem Cells and Cervical Cancer
Cancer statistics shows that cervical cancer is the fourth most common cancer in
women, and the seventh overall, with an estimated 528,000 new cases in 2012
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worldwide, while it remains the most common cancer in women in Eastern and Middle
Africa. Interestingly, 87% of cervical cancer deaths occur only in the less developed
regions [49], possibly due to less screening techniques.
Cancer stem cells (CSCs), a subset of cancer cells (0.1- 30%) with self-renewal
and differentiation potential, have been implicated in tumor initiation, maintenance,
metastasis, and recurrence of a number of cancer types [50, 51]. To identify and isolate
CSCs from within a heterogeneous population of cancer cells, recent studies have shown
that aldehyde dehydrogenase family 1 (ALDH1) is a CSC marker that associates with
tumor malignancy and self-renewal properties of stem cells in different tumors,
including breast [52], colon [53], and cervical [54, 55] cancers.
PEITC is a dietary bioactive compound derived from common Brassicacae
family cruciferous vegetables, such as watercress, broccoli, cabbage, and cauliflower
[56]. PEITC possesses anti-inflammatory [57, 58] and chemopreventive activity against
various cancers, including colon [59], breast [60], cervical [61, 62] cancers. PEITC has
no apparent toxicity, as revealed from safety studies in rats and dogs, even when
administered in high doses determined by NOEL (no-observed-adverse-effect-level)
[63]. Remarkably, undergoing clinical trials in the US has elucidated the protective role
of PEITC against lung cancer (NCT00691132). This is the basis of our working
hypothesis under chapter 5 that PEITC selectively targets chemo-and-radiotherapy
resistant cancer initiating CSC) in a suitable mouse model.
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1.7. Dissertation Organization
The whole dissertation research has yielded five research papers as described in
subsequent chapters. Two of them are published, one is accepted for publication, and the
remaining two papers are in preparation. These chapters are preceded by a general
“Introduction”, while specific literature review is provided within the specific chapter,
followed by a general “Conclusion”. All the figures and tables belonging to the same
chapter are placed at the end of each chapter. The references are cited in a numbered
fashion as they appear in the text and are compiled altogether at the end of this
document.
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Figure 1.1. Nutrigenomics
A model emphasizing nutrient-gene interaction responsible for health and disease status
(modified from Peter Gillies [2]).
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Figure 1.2. A dynamic extrinsic and intrinsic factors affecting gut epithelial
permeability.
Epithelial monolayer separates luminal gut microbiota and their metabolites from
underlying mucosal immune cells. Tight-junction proteins (TJPs) hold adjacent
epithelial cell together to prevent paracellular bacterial translocation into the gut
mucosa. The disequilibrium or dysbiosis determines the fate of epithelial cells whether
to activate mucosal immune system through microbial pattern recognition receptor
called toll-like receptors (TLRs) or to activate enterocyte apoptosis to turnover. Dietary
bioactive components like PEITC and dietary fiber like RS4 modulate gut epithelial
integrity maintaining the fine balance between health and disease.
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Table 1.1. Types of resistant starch and their food sources (modified from Topping
and Clifton [22])
Types of Resistant Starch

Examples of Occurrence

RS1; physically inaccessible

Partly milled grains and seeds

RS2; resistant granules

Raw potato, green banana, some
legumes, and high-amylose starches

RS3; retrograded

Cooked and cooled potato, bread, and
cornflakes

RS4; chemically modified

Etherized, esterified, or cross-bonded
starches (used in processed foods)

RS5; amylose-lipid complex

Stearic acid-complexed high-amylose
starch

RS: Resistant starch
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CHAPTER 2 . IMPACT OF DIETARY RESISTANT STARCH TYPE 4 ON
HUMAN GUT MICROBIOTA AND IMMUNOMETABOLIC FUNCTIONS

Related publication: Upadhyaya, B. et al. Impact of dietary resistant starch type 4 on
human gut microbiota and immunometabolic functions. Sci. Rep. 6, 28797; doi:
10.1038/srep28797 (2016)

2.1. Abstract
Dietary modulation of the gut microbiota impacts human health. Here we
investigated the hitherto unknown effects of resistant starch type 4 (RS4) enriched diet on
gut microbiota composition and short-chain fatty acid (SCFA) concentrations in parallel
with host immunometabolic functions in twenty individuals with signs of metabolic
syndrome (MetS). Cholesterols, fasting glucose, glycosylated hemoglobin, and
proinflammatory markers in the blood as well as waist circumference and % body fat
were lower post intervention in the RS4 group compared with the control group. 16SrRNA gene sequencing revealed a differential abundance of 71 bacterial operational
taxonomic units, including the enrichment of three Bacteroides species and one each of
Parabacteroides, Oscillospira, Blautia, Ruminococcus, Eubacterium, and
Christensenella species in the RS4 group. Gas chromatography–mass spectrometry
revealed higher fecal SCFAs, including butyrate, propionate, valerate, isovalerate, and
hexanoate after RS4-intake. Bivariate analyses showed RS4-specific associations of gut
microbiota with host metabolic functions and SCFA levels. Here we show that dietary
RS4 induced changes in the gut microbiota are linked to its biological activity in
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individuals with signs of MetS. These findings have potential implications for dietary
guidelines in metabolic health management.
Keywords: 16S-rRNA gene sequencing, gut microbiota, resistant starch type 4,
short chain fatty acids, bowel health

2.2. Introduction
Metabolic syndrome (MetS) encompasses co-morbidities like obesity,
dyslipidaemia, hypertension, insulin resistance, and hyperglycaemia, which increase the
risk of cardiovascular diseases [64], the leading cause of death in the US [65]. Although
it is possible to manage these co-morbidities with dietary/lifestyle changes and/or
therapeutic interventions, the overall prevalence of MetS is rising worldwide [65, 66].
One contributing factor could be non-adherence to healthy dietary practices beyond the
short term, as convenience and taste remain the strongest determinants of food choices
[67, 68]. In that context, our recent double-blind study allowed participants to maintain
their habitual dietary practices during the intervention without adapting to any change
[25]. This was possible due to the neutral and adaptable organoleptic properties of the
resistant starch (RS) type 4 (RS4), a wheat-derived food-ingredient, used for the
intervention.
Different chemical properties contribute to the functional differences between five
RS types, particularly in terms of fermentability and its influence on the microbiota in the
gut [69]-[24]. Fermentable carbohydrates such as RS4, may potentially increase colonic
short-chain fatty acid (SCFA) production [70]. However, there remains a dearth of wellcontrolled intervention studies that have comprehensively examined the influence of RS4

15
on host physiological, gut microbiome, and SCFA changes [71-73]. One study reported
influence of RS4 in healthy individuals, unrelated to any metabolic condition [24]. Other
published studies regarding metabolic health benefits of RS4 involved animal models
[74-76]. However, due to various metabolic adaptations in MetS patients, they may not
always benefit from the information generated in healthy humans or animal models [77].
Taken together, there is a critical need for well-designed studies in individuals with MetS
that systematically connects the influence of a functional and adaptable food ingredient
on the gut microbial community, bacterial metabolites like SCFAs, and host metabolic
functions.
In our trial, the RS4-group had an improved lipid profiles and body composition
[25]. Since RS4 is indigestible, we hypothesized that the health benefits of RS4 are
derived from its ability to influence the gut microbial community structure, which may,
in turn, be linked to altered bacterial fermentation and SCFA production [22]. Therefore,
here, in selected participants with MetS, we retrospectively examined the changes in the
microbiota composition and the SCFA production in the gut, measured the concentrations
of three circulatory adipocytokine markers, and estimated the macronutrient and caloric
intake during the intervention period. Also, the host anthropometric and metabolic
parameters were reanalysed in this cohort to show microbe-microbe and host-microbe
interactions.

2.3. Materials and Methods
Subjects
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Participants in this study included a subset of the parent cohort consisting of 20
individuals who originally participated in a dietary intervention with RS4 [25]. Briefly,
this study was conducted in an adult population, consisting of both males and females,
from two Hutterite colonies in eastern South Dakota, USA. The Hutterites are a culturally
homogeneous Caucasian population of Central European ancestry. The parent trial is
registered in clinicaltrials.gov (NCT01887964). From 40 participants who had signs of
metabolic syndrome at baseline, 26 subjects submitted stool samples at all four data
collection time points. Out of 26, 20 subjects (10 from each of the two colonies) were
included in the current investigation as their fecal samples were adequate to carry out
both sequencing and short chain fatty acid (SCFA) analyses (Figure 2.1). The selected
cohort included 12 females and eight males, aged 32-77 (Table 2.1). Exclusion criteria
included pregnancy, lactation, long-term antibiotic therapy, immune compromised state,
cancer, and other conditions that would affect the ability to provide informed consent or
comply with the protocol.

Test Diets
Participants consumed control flour (CF) and resistant starch type 4(RS4) flours
as described in Nichenametla et al. [25]. RS4 flour was made by substituting 30% (v/v)
of the CF with RS4 (Fibersym RW, MGP Ingredients Inc., Atchison, KS). The sequence
of flour consumption was randomly assigned to the colonies. Dietary intake was assessed
by using a 3-day (2 weekdays and 1 weekend day) semi-quantitative food-frequency
questionnaire, customized to include foods that Hutterites frequently consume, mostly
consisting of items cooked from raw ingredients. Evidence show that the Hutterites
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consume more fresh produce in summer and preserved or frozen food in winter resulting
into a diet-influenced shifts in microbiome [78]. Since the study period did not overlap
with winter months, the impact of seasonal variation on gut microbiome was not
considered. Diet analysis was performed using Nutritionist Pro (Axxya Systems,
Redmond, WA, USA) to obtain macro-nutrient breakdown of the consumed diets. Diet
information was collected using a self-administered semi-quantitative food frequency
questionnaire and was analysed using Nutritionist Pro (Axxya Systems, Redmond, WA,
USA). Anthropometric, blood lipids, glycaemic parameters, and blood pressure
measurement data were obtained from the parent study and reanalysed in this sub-cohort
[25].

Study design
The original trial [25] was conducted as a two-period, total 26-week long double
blind (participants–investigators), placebo-controlled, cluster cross-over intervention
(Figure 2.1a). Each intervention period (CF and RS4) was for 12 weeks with a washout
time of two weeks in between. All data and bio specimens were collected on-site from
both colonies at baseline, 12, 14, and 26 weeks except body composition analyses, which
were carried out at baseline, 12 and 26 weeks. A modified CONSORT flow chart is
provided (Figure 2.1b). The study was conducted under free-living conditions, and no
dietary restrictions were imposed. Gastrointestinal symptoms and stool consistency were
scored based on a one-on-one interview with the participants [25]. Current and past
medical information were obtained at each visit, which included medication or dietary
supplement use, menopausal status, medical conditions, and hospital stays. Seven-day
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physical activity-recall questionnaires were administered by trained staff to assess any
atypical physical activity.

Anthropometric measurements
Height, weight, waist circumference, and blood pressure were measured at the
beginning and at the end of each intervention period following standard procedures that
were previously described [79]. Briefly, height was determined using a stadiometer and
recorded to the nearest 0.5 cm. Body weight was measured on an electronic scale (Seca
GmbH & Co., Hamburg, Germany) with the subjects in light clothes and no shoes and
was recorded to the nearest 0.1 kg. Waist circumference was measured at the navel using
a tension-sensitive, non-stretching Gulick tape and recorded to the nearest 0.5 cm.
Blood pressure was measured with a digital sphygmomanometer in a sitting position.
Body composition (fat mass and fat-free mass) was determined by total-body, dualenergy, x-ray absorptiometry (DXA) scanning (Hologic QDR Discovery A, Waltham,
MA) as described previously [80]. Fat mass is presented as % body fat in paper.

Blood biochemistry
Overnight fasting blood was collected by venepuncture in vacutainer tubes (BD
Biosciences, Franklin Lakes, NJ). Fasting blood glucose, total cholesterol (TC), LowDensity-Lipoprotein cholesterol (LDL), High-density-Lipoprotein cholesterol (HDL),
non-HDL cholesterol (non-HDL), triglycerides were determined using the Cholestech
LDX point-of-care analyzer (Alere Inc, Waltham, MA), lipid profile and glucose
cassettes (Lipid Profile GLU, Alere Inc, Waltham, MA), following the manufacturers’
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instructions. Postprandial glucose was determined 2 h after either breakfast or the noon
meal by using a FreeStyle Freedom Lite blood glucose meter (Abbott Diabetes Care Inc,
Alameda, CA), following the manufacturer’s instructions. Participants typically
consumed a food item made with test flour during the meal prior to the postprandial
glucose test. Glycosylated hemoglobin (HbA1C) was determined by an enzyme-based
colorimetric assay using the Human HbA1C kit (Crystal Chem, Downers Grove, IL),
following the manufacturer’s instructions. Each sample was run in duplicate, and a batch
control was used to account for inter-assay variation. HbA1C levels were expressed as
the percentage of total hemoglobin. Two markers of inflammation, interleukin 6 (IL6)
and tissue necrotic factor-α were determined (in duplicate) in serum using Human ELISA
Ready-SET-Go kits, following the manufacturer’s instructions (eBioscience, San Diego,
CA). Plasma adiponectin levels, an indicator of metabolic functions, were detected by
Human Adiponectin Radioimmunoassay following the manufacturer’s instructions
(Linco Research, St. Charles, MO). Inter- and Intra-assay coefficients of variance were
5.0% and 11.7%, respectively.

Fecal SCFA analysis by gas chromatography-mass spectrometry (GC-MS)
SCFAs were derivatized to their corresponding butyl esters (SCFABE) followed
by GC-MS analyses using a GC-MS 5977A and HP-5MS UI capillary column from the
same manufacturer (Agilent, Wilmington, DE, USA). The data were expressed in mg/gm
of fecal sample. To prepare fecal samples for SCFA analyses, 800-1000 mg fecal sample
was homogenized and added to a glass tube containing 1 ml of internal standard (2ethylbutyric acid in 1-butanol, 1 mg/mL). Organic solvent hexane and derivatizing agents,
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hydrogen chloride 1-butanol or Boron trifluoride 1-butanol (both from Sigma-Aldrich, St.
Louis, MO), were then added with vortexing between each addition. Boron trifluoride 1butanol and hydrogen chloride 1-butanol were used to create butyl-esters for SCFA
detection. Samples were then sonicated and placed in water bath (90-100 0C) for 1h.
Once cooled to room temperature, water and additional hexane were added to the samples
and centrifuged at 3000g for two min. The organic layer (~2 mL) was transferred into a
sampling vial with 150 µL inserts, finally adding a pinch (~10 mg) of anhydrous sodium
sulphate to remove the residual water. Fecal extracts were stored at -20 0C until further
analysis.
GC-MS analyses were performed with an GC-MS 5977A (Agilent Technologies,
Wilmington, DE, USA) and an HP-5MS UI capillary column (30 m x 0.25mm, 0.2 µm
thickness, Agilent, Wilmington, DE, USA). Hydrogen was used as carrier gas at 1.9
mL/min constant flow and a typical injection volume was 1 µL in the split mode (1:10).
The separation of SCFA butyl esters was achieved using an oven temperature program as
follow: initial elution temperature was 55 0C for 4 min then 5 0C/min to 120 0C and then
20 0C/min to 220 0C for 10 min. The selective mass detector was operated in the ‘single
ion monitoring and scan’ (SIM/Scan) mode. The source was maintained at 150 0C and the
electron energy was 70 eV.

Community structure analysis of gut microbes
Stool DNA was extracted using the QIAamp DNA Stool Mini Kit (QIAGEN,
Valencia, CA) according to the manufacturer’s instructions. All samples were quantified
via the Qubit® Quant-iT dsDNA Broad-Range Kit (Invitrogen, Life Technologies, Grand
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Island, NY). Sample DNAs were sent to Second Genome (South San Francisco, CA) for
metagenome sequencing, and operational taxonomic unit (OTU) identification. Briefly,
samples were enriched for bacterial 16S V4 rDNA region, DNA was amplified utilizing
fusion primer designed against the Illumina (San Diego, CA) flow cell adapters and
indexing barcodes. Each sample was PCR-amplified with two differently bar coded V4
fusion primers. For each sample, amplified products were concentrated using a solidphase reversible immobilization method for the purification of PCR products and
quantified by electrophoresis using an Agilent 2100 Bioanalyzer® (Agilent Technologies,
Santa Clara, CA). Sequencing was carried out using Illumina MiSeq platform following
standard protocols for 250 cycles with custom primers designed for paired-end
sequencing. Using Quantitative Insights Into Microbial Ecology or QIIME [81] and
generated custom scripts (Second Genome), sequences were quality-checked and
demultiplexed to determine exact matches to the supplied DNA barcodes. Resulting
sequences were then searched against the Greengenes reference database of 16S rRNA
gene sequences, clustered at 97% by uclust (closed reference OTU picking). The longest
sequence from each OTU was then assigned taxonomic classification via Mothur's
Bayesian classifier, trained against the Greengenes database clustered at 98%. For
unidentified Greengenes OTUs, we cross referenced with closest hits from NCBI 16S
rRNA database with query cover (>90%), identity (>87%), and E value (<0.01). Raw
sequences are deposited in NCBI sequence read archive (SRA, accession number
SRP035338), belonging to BioProject accession number PRJNA308315.
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Statistical analyses
Data analyses were performed using two approaches. Effects of CF and RS4
interventions were determined by comparing end-point data, while effects of RS4
intervention alone was presented by comparing the data before and after RS4 intervention.
Linear mixed effects models (SAS MIXED procedure) were used to compare the effects
of RS4 and CF on biological parameters. All models included variables for colony and
season, where colony was a surrogate for randomization sequence and season was a
surrogate for crossover treatment period. Because the crossover design used only two
clusters (colonies), and any carryover effect might be confounded by cluster sampling
effect (colony effects), thus a carryover effect could not be independently evaluated in the
mixed models. Covariates for age, sex, baseline value of the outcome variable, change in
total calorie intake were evaluated for their association with the response variables, and
covariates that significantly affected at least one outcome variable were retained in the
final model as fixed effects. The final models included season, colony, sex, age, and
initial baseline value of the response variable as fixed effects.
When appropriate data were presented for either all-participants or stratifying
participants based on missing data or outliers in microbial changes as our observations
concur with a prior report of large inter-subject variations in response to RS4 [24]. For
microbiome analyses one subject was excluded (n=19) because of Lactobacillus probiotic
supplement use during the RS4 intervention period. For multivariate analysis PhyCAStats™ software package (Second Genome Inc, South San Francisco, CA) was utilized.
Differences in the bacterial taxa and host phenotypes among time points were determined
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by paired t-test or student’s t-test as appropriate. If the data were not normally distributed,
values were subjected to logarithmic transformations as indicated.
Two approaches for sampling normalization were employed to account for
uneven sequencing depth during data analyses on metagenome sequencing. First, taxa
were filtered to those present in at least one of the samples, selecting 55,079 sequences
from each sample before calculating community-wide dissimilarity measures. This
facilitated calculations of microbial relative abundances (Figures 2.2, 2.4b, 2.6b, 2.7, and
2.8), and principal coordinate analyses (Figure 2.3). Second, the samples were
normalized to 1 million counts. Thus the shift in microbial profile between the samples or
groups was calculated based on per million sequences, which facilitated calculations of
71 differentially abundant OTUs or species (Figures 2.4a and 2.4c).
We used various R-packages (http://www.r-project.org/) for downstream data
analyses on gut microbiome. Package edgeR
(http://www.bioconductor.org/packages/release/bioc/html/edgeR.html) [82] which has
the distinct benefit of increasing the sensitivity of detecting differentially abundant
features, was utilized to control for inter-subject variability because of a model-based
normalization to adjust for varying sequencing depths. This approach of identifying
differentially abundant taxa between treatments borrows from the RNA sequencing
literature testing for differential gene expression. These methods have recently been
demonstrated to effectively translate to microbiome analyses [83], offering a robust
method with options for paired sample comparisons even for experiments with minimal
levels of biological replication. To correct for multiple comparisons, a false discovery
rate correction was used to correct for p-values (adjusted p is represented as q). In order
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to generate correlation matrices and heat maps, several R-packages, namely Hmisc
(http://CRAN.R-project.org/package=Hmisc) [84], corrplot (http://CRAN.Rproject.org/package=corrplot) [85], gplots (http://CRAN.R-project.org/package=gplots)
[86], and ecodist (https://CRAN.R-project.org/package=ecodist) [87] were used.
Significant variation in microbiome baseline values between intervention-groups were
ruled out using a Permutational Multivariate Analysis of Variance that also confirmed the
effectiveness of the washout period. Two-dimensional Principal Coordinate Analysis
(PCoA) followed by Adonis test was used for plotting dissimilarity values so that the
similar data points get closer to each other. Statistical analyses were carried out using
Sigma Plot software (Systat Software, Inc., San Jose, CA) and the data were presented as
means±S.E.M, unless otherwise noted. A p value of 0.05 or less was considered
significant, while a p value of 0.05 to 0.09 was considered trend or approaching
significance.

2.4. Results
Baseline physiologic, metabolic, and microbiome characteristics of the study
participants
All twenty participants who had signs of metabolic syndrome at baseline and
submitted adequate stool samples at four data collection time points were included in the
current investigation (Figure 2.1), which allowed for comparison of the gut microbial and
SCFA profiles before and after the interventions and also between the endpoints of the
RS4 and CF (control) interventions. Potential adverse gastrointestinal side effects from
the interventions were not evaluated in this cohort since none were observed in the parent
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cohort [25]. Baseline characteristics of 20 participants are summarized in Table 2.1.
Taxonomic classification of a total of 55,079 sequences (present in at least one of the
samples) were sorted into 5,949 OTUs, of which ~78% were associated with the phylum
Firmicutes and ~9% with the phylum Bacteroidetes (Figure 2.2).

Washout was effective in restoring microbiome characteristics
Before switching the RS4 and CF diets in the cross-over study design, all the
participants were supplied with CF during the 2-week washout period in order to avoid
the potential carry-over effects of the RS4 intervention. For endpoint comparison
between the RS4 and CF groups, it was necessary to check for a consistent baseline prior
to each treatment period. Using permutational multivariate analysis of variance for
distance matrices, no significant differences were observed among the starting
microbiomes of the RS4 and CF groups (data not shown), which also confirmed that the
two-week washout was effective and that any differences observed post-intervention are
due to the intervention itself.

Macronutrient intake pattern did not vary during the study
Variation in macronutrient intake and total calories consumed can potentially
influence the gut microbiota [88], thereby confounding the effects of the intervention.
Although a large number of food options are offered at each meal, Hutterites have
relatively small interpersonal differences in diet due to common meal planning, kitchen,
and dining practices. No significant differences in overall macronutrients and caloric
intake were observed between the baseline and post-intervention time periods, with the
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exception of dietary fiber (Table 2.2). Dietary fiber intake, analysed separately from total
carbohydrate intake, was significantly higher in the RS4 group (p<0.001), due to RS4
being classified as a prebiotic dietary fiber (Table 2.2). The average calories (~1,774
Kilocalories) consumed at baseline were estimated to come from carbohydrate (~49%),
protein (~17%), and fat (~34%). These values fall within the Dietary Reference Intakes
(DRI) for macronutrients, which are 45–65%, 10–35%, and 20–35% for carbohydrate,
protein, and fat, respectively [89]. Of particular interest, saturated fat (12.6%, DRI<10%)
and cholesterol (415 mg, DRI<300 mg) intakes were higher, while daily fiber intake was
lower (18 g at baseline, DRI 20–30 g) than recommended in the participants studied.

Differential post-intervention effects of the RS4 diet compared with the CF diet on
the gut microbiota
The current understanding is that, in studies without a proper control group, interindividual variation in gut microbial composition in adults frequently offsets the smaller
changes induced by dietary interventions [71]. To address this problem, we compared
microbial composition and abundance post RS4 compared with post CF intervention.
Three taxa, all unclassified species of Firmicutes, differentially shifted between CF and
RS4 treatments in eight male participants. Similarly, a differential effect of RS4 was
observed in 16 Firmicutes taxa, with the most numerous genus being Enterococcus,
which was significantly enriched after CF intake in 12 female participants (data not
shown). No distinct trend for Firmicutes to Bacteroidetes ratio was observed in male or
female participants (data not shown). The dominance of Firmicutes and Bacteroidetes
was consistent with previous results, as reported in Hutterite [78] and other populations
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[90]. The Shannon diversity index was not associated with the age of the participants
(r=−0.2, p>0.05, data not shown). Likewise, the total diversity of the microbiota assessed
from the Shannon diversity index did not significantly change after either CF or RS4
interventions (data not shown).
Principal coordinate analysis showed 26% and 13% variations on axes 1 and 2,
respectively, indicating a major shift between the two groups (p=0.01, Figure 2.3). The
RS4 diet differentially modified 71 microbial OTUs (q<0.05), including enrichment of
four each of Ruminococcus and Blautia, two each of Bacteroides and Oscillospira, and
one Parabacteroides OTUs (data not shown). Of the 71 OTUs, 65 belonged to the
phylum Firmicutes. The three Bacteroidetes OTUs all increased in abundance with RS4
relative to the CF treatment, while OTUs belonging to Firmicutes had a mixed response
(data not shown). At the species level, some species were significantly enriched in the
RS4 group, including three Bacteroides species (>121.2 fold, q<0.05) along with Blautia
glucerasea (2497.1 fold, q<0.001), Christensenella minuta (2.4x106 fold, q<0.001),
Eubacterium oxidoreducens (7723.2 fold, q<0.01), Oscillospira spp. (2528.4 fold,
q<0.01), Ruminococcus lactaris (1.2x105 fold, q<0.001), and Parabacteroides distasonis
(8642.2 fold, q<0.001), while some were significantly decreased in abundance in this
group, including pathogenic Enterococcus casseliflavus (–13603.2 fold, q<0.001) and
Streptococcus cristatus (–229.7 fold, q<0.05) (Figure 2.4a). Although the enrichment
fold changes for some of the bacterial species appear very high, their relative abundance
in the whole microbial community could be low. This is due to the commonly used
sampling normalization approach based on per million sequences to remove any bias due
to varying sequencing depth (details in Methods). Overall, trends showed that
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Bacteroidetes OTUs were increased in the RS4 group, leading to an overall lowering of
the average Firmicutes-to-Bacteroidetes (F:B) ratio in the RS4 group from 14.6 at
baseline to 12.9, but increasing to 19.2 post CF diet (Figure 2.4b). The lower F:B ratio is
frequently perceived as an indicator of a leaner phenotype, although the previously
reported results are not always consistent [91]. Firmicutes and Bacteroidetes are two
major phyla and the species composition within each may vary widely in a given subject.
It is possible that both phyla include species that may be characteristic of a particular
phenotype. Therefore, a species level composition may represent a body weight
phenotype more precisely than a broad estimation of F:B ratio.

Impact of RS4 on gut microbiota composition compared before and after RS4
intervention
Firmicutes species from Clostridium cluster XIVa account for almost 60% of the
mucin-adhered microbiota [92]. A general observation was that species from Clostridial
cluster XIVa, but not cluster IV, were enriched by RS4 supplementation of the diet. At
the species level (Figure 2.4c), RS4 consumption increased the abundance of
Bifidobacterium adolescentis (90.5 fold, q=0.087) and Parabacteroides distasonis
(1180.2 fold, q<0.001) but not Ruminococcus bromii (−3.2 fold, q>0.05),
Fecalibacterium prausnutzii (−1.2 fold, q>0.05), or Dorea formicigenerans (1.1 fold,
q>0.05), which confirmed the previous report [24]. Novel observations include an RS4induced increase in Christensenella minuta abundance (119.7 fold, q=0.038, 97% query
coverage, 88% identity and E<0.001 in NCBI-BLAST) as well as in several OTUs in the
family Ruminococcaceae and genus Bacteroides. At the species level, Bacteroides ovatus
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(37.6 fold, q=0.087), Ruminococcus lactaris (2866.7 fold, q<0.001), Eubacterium
oxidoreducens (3.3x105 fold, q<0.001), Bacteroides xylanisolvens (47.8 fold, q=0.037),
and Bacteroides acidifaciens (92.4 fold, q=0.038) were enriched after RS4 intervention.

RS4 consumption altered fecal SCFAs linked to specific gut microbes
Acetate was the most abundant SCFA, accounting for over 60% of total SCFAs
before and after the interventions in both RS4 and CF groups. The individual proportions
of the SCFAs, butyric (69.5%, p=0.03), propionic (50.2%), valeric (44.1%), isovaleric
(20.3%), and hexanoic (19.2%) acids increased post intervention from baseline in the
RS4 group (p<0.05, Figures 2.5 and 2.6a) but not in the CF group (data not shown). A
24.6% decrease in isobutyric acid in the RS4 group was observed. A Pearson correlation
analysis showed a potential link between significant changes in the gut microbiota
composition induced by RS4 and altered SCFA levels (Figure 2.6b). Acetate and butyrate
levels were correlated (p<0.05) with Ruminococcus lactaris (r=0.54) and Oscillospira
spp. (r=0.41). Total SCFAs were correlated with the abundance of two species:
Methanobrevibacter spp. (r=0.43) and Ruminococcus lactaris (r=0.52). Propionate and
isobutyrate levels were linked to Methanobrevibacter spp. (r=0.65 and r=0.79,
respectively), Eubacterium dolichum (r=0.42 and r=0.43, respectively), Christensenella
minuta (r=0.39 and r=0.59, respectively), and Ruminococcus lactaris (r=0.59 and r=0.40,
respectively), of which the latter two were increased by RS4 (Figure 2.4a, 2.4c, and 2.6b).
Interestingly, these associations of SCFAs with specific gut microbiota were not observed
after CF intervention (data not shown). To our knowledge, prior studies with RS4 have
not reported significant SCFA changes in human fecal samples.
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Impact of RS4 intervention on circulatory adipocytokines
In obesity, macrophages infiltrate adipose tissue and secrete proinflammatory
cytokines such as IL6 and TNF-α [93]. Also, adiponectin is released by adipocytes in the
blood and has important roles in lipid and glucose metabolism [94]. Reduced adiponectin
levels are associated with various aspects of metabolic dysfunction [95]. Compared with
baseline, IL6 decreased by 38% (p=0.04), and adiponectin levels increased by 20%
(p=0.002) in the RS4 group, while TNF-α did not change significantly. Both TNF-α and
adiponectin concentrations were lower post RS4 diet compared with post CF diet (p=0.08
and p=0.02 respectively, Table 2.3). To our knowledge, this is the first report showing
changes in adipocytokines, which help determine progression to cardiovascular
aberrancies [95, 96], in response to RS4 intake in humans.

Impact of RS4 consumption on body composition, lipids, and glucose metabolism
Individuals had lower % body fat (p=0.05) and lower non-high density lipoprotein
(non-HDL, p=0.003), HDL (p=0.005), and total cholesterol (TC, p<0.001) post RS4
consumption compared with post CF consumption (Table 2.3). A trend was observed for
lower waist circumference (p=0.06), glycosylated hemoglobin (HbA1C, p=0.08), and
fasting blood glucose (p=0.09) following RS4 consumption compared with CF
consumption. It is likely that response variation among participants to an RS4 diet
contributed to these higher p-values. Varying responses to dietary interventions among
individuals are frequently reported [97]. Changes in fasting glucose and HbA1C were
more pronounced in this cohort (−8.6% and −1%, respectively) compared with the parent
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cohort (−4.2% and no decrease, respectively). Attenuation of % body fat combined with a
smaller waist circumference indicates a potential reduction in central obesity in these
individuals. Although significant, these changes were modest, as measures of body
composition do not change rapidly in adults and can take several months to years to show
a larger change. Waist circumference, TC, HDL, and non-HDL were also reduced in the
RS4 group compared with baseline (all, p<0.05). No significant effects of RS4 were
observed on blood pressure or triglyceride levels in either group (Table 2.3). The average
lipid and glycaemic profiles were apparently within normal limits, likely due to
prescribed medication usage for various metabolic dysfunctions (Table 2.1).

Inter-associations between gut bacteria and metabolic functions
Multiple novel gut microbial associations with metabolic functions were observed
post intervention in the RS4 group compared with the CF group (Figure 2.7). We propose
that the associations detected post RS4 diet, but not post CF diet, could be induced by
RS4. However, several associations were common to both groups, lacking specific
response to RS4 enrichment. RS4-specific inverse correlations were observed between
TC and the abundances of Bacteroides plebeius (r=−0.46), Blautia producta (r=−0.49),
and Prevotella stercorea (r=−0.45; all, p<0.05). Although the abundances of
Parabacteroides distasonis and Oscillospira spp. were enriched post RS4 compared with
post CF intervention, their negative association with TC, low-density lipoprotein (LDL),
and non-HDL were not RS4-specific (all, p<0.05). In another instance, while RS4 did
not significantly alter the abundance of Fecalibacterium prausnitzii, an RS4-specific
negative correlations between this species and body mass index (BMI, r=−0.45) and %
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body fat (r=−0.56) were observed (all, p<0.05). An RS4-specific correlation between
adiponectin and Bacteroides ovatus (r=0.79, p<0.01), Bacteroides uniformis (r=0.56,
p<0.05), and Bacteroides acidifaciens (r=0.82, p<0.001) was observed (Figure 2.7). RS4
intake did not significantly enrich Methanobrevibacter spp. and Eubacterium dolichum,
but these bacteria were correlated with weight and BMI (Figure 2.7) as well as with
SCFA levels (Figure 2.6b) in an RS4-specific manner. Methanobrevibacter spp.
(r=−0.45), Ruminococcus gnavus (r=−0.56), and Prevotella stercorea (r=−0.45) were
negatively correlated with LDL (p<0.05), while Blautia producta (r=−0.44) and
Prevotella stercorea (r=−0.50) were negatively associated with TC and non-HDL (all,
p<0.05) in an RS4-specific way.

Intra-association within gut microbes
Little is known about how the relative abundance of one microbial species may
influence the presence of another species within the gut ecosystem, particularly in
response to RS4 consumption. To evaluate this question, we examined intra-association
and clustering among those bacteria that showed RS4-specific association with SCFAs
and metabolic features. Three Bacteroides species that showed a positive correlation with
adiponectin and Prevotella stercorea, which associated with TC, LDL, and non-HDL,
were clustered together (Figure 2.7 and 2.8). In general, a higher association within
Bacteroidetes species or within Firmicutes species was observed, although there were
exceptions. One example is Bacteroides plebius, which correlated with the Firmicutes
member Blautia producta (r=0.98, p=<0.001), and both of these were negatively linked
to RS4-induced changes in TC or non-HDL. Christensenella minuta tended to associate
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with Ruminococcus lactaris (r=0.58, p=0.02), and both were enriched after RS4
intervention. Both Christensenella minuta and Ruminococcus lactaris also clustered with
Methanobrevibacter spp. and Eubacterium dolichum (both p<0.05), but not with
Ruminococcus torques and Oscillospira spp., although all of them were associated with
one or more SCFAs (2.6b and 2.8).

Association among metabolic features
Variation in response to RS4 among participants was observed, and the pattern is
similar for various host metabolism parameters (response variation data not shown). This
pattern may be due to the known link between high levels of circulating lipids and
glucose with lower blood adiponectin levels [98] and the correlation of up-regulated IL6
and tissue necrotic factor-α with the pro-inflammatory state in obesity [99]. The
clustering of metabolic dysfunctions and CVD risk factors in adults has been observed in
epidemiological studies and in the clinical setting [100]. In line with that, we observed
consistent intra-associations among parameters of metabolic dysfunction within our data
set independent of dietary changes (Figure 2.9). TC and non-HDL, but not HDL,
correlated more closely with each other (r=0.95, p<0.001). Similar correlations were
observed among various anthropometric measures, such as weight, BMI, and waist
circumference, as well as fasting glucose (p<0.05). Fasting glucose correlated with IL6
level (r=0.51, p=0.07), which in turn was associated with diastolic blood pressure (r=0.78,
p<0.01), systolic blood pressure (r=0.52, p=0.07), and waist circumference (r=0.60,
p=0.03). Triglyceride concentrations were positively associated with weight (r=0.82,
p<0.001), waist circumference (r=0.60, p=0.03), and BMI (r=0.64, p=0.02), while
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negatively correlated with HDL (r=−0.65, p=0.02) and adiponectin (r=−0.45, p=0.12) but
had little apparent link with TC and LDL.

2.5. Discussion
Our present study provides for the first time a microbiome signature in response
to RS4 consumption in subjects with MetS. Among the comorbidities of MetS,
numerous studies associated a dysbiosis with obesity and type 2 diabetes [101], but less is
known about the role of the microbiota-diet interactions in hypercholesterolemia [102]. A
handful of in vitro, animal, and healthy volunteer studies suggested that the microbiota
affects lipid metabolism [103-105], but a clear understanding is lacking. Reduction in
plasma TC and non-HDL and HDL cholesterol after RS4 consumption was consistently
observed in the larger parent cohort [25] as well as in the present sub-cohort when
compared with the control group and with baseline. In addition, a novel link between TC
and non-HDL with three bacterial species was observed in an RS4-specific manner. The
effect of an RS4 diet on Parabacteroides distasonis without any context of lipid
metabolism was previously reported [24] and further confirmed by our results.
Parabacteroides distasonis was augmented post-RS4 compared with the post-CF and
baseline. This species showed a correlation with TC and non-HDL in both intervention
groups and clustered with species belonging to both the Bacteroidetes and Firmicutes
phyla. While RS4 also lowered HDL, such a reduction is not always associated with
increased cardio-vascular disease risk, while lowering of TC and non-HDL, which
includes LDL, remains critical [106].
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Another novel RS4-induced microbial enrichment involved Christensenella
minuta in the family Christensenellaceae, which was identified in human faeces only
recently [107]. This species was reported as being heritable, based on host genetics, and
abundant in healthy, lower-BMI individuals, and its addition reduced microbiomemediated weight gain in germ-free mice [108]. Christensenella minuta was enriched post
RS4-diet compared with post CF-diet and the baseline, and correlated in an RS4-specific
manner with higher propionate, isobutyrate, valerate, and isovalerate concentrations,
similar to that of Methanobrevibacter spp. in the Methanobacteriaceae family. This result
is in line with a previous report that this bacterium co-occurs with Methanobacteriaceaea
members, and both together produce SCFAs [108]. Moreover, Christensenella minuta
was reported to augment Oscillospira, a bacterium that was enriched and associated with
higher isovarelate levels post-RS4 but not post-CF. However, contrary to a prior
suggestion [108], our results present evidence that Christensenella minuta is amenable to
dietary intervention. We also observed a positive correlation of this species with weight
and BMI, which was, however, non-specific to RS4 intervention. Future investigations
may address whether Christensenella minuta-mediated energy harvest from SCFAs is
utilized differently by individuals with MetS than by the lean and healthy individuals
involved in prior studies [107, 108].
Complex carbohydrate or glycan availability is a major factor in shaping the gut
microflora [109]. Since many of the starch-degrading enzymes are represented as a
starch-utilization system (SUS) in ~20% of the genome of Bacteroidetes species [109111], enrichment of Bacteroides ovatus and Parabacteroides distasonis after RS4
intervention in this study was as expected. Further confirmation with Carbohydrate-
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Active Enzymes (CAZy) database (http://www.cazy.org/) [112] supported that
Bacteroidetes species are dominant starch-degrading bacteria after RS4 intervention.
The strengths of this study include statistically significant observations of
prebiotic RS4-induced changes across microbial composition, fecal SCFA levels, and
host immunometabolic functions, all of which are relevant to the underlying physiology
of individuals with pre-existing metabolic dysfunctions. Human dietary interventions
conducted within natural settings and reporting statistically significant outcomes that are
consistent across a broad range of metabolic health measures are rare [113]. One
exploratory human intervention study attempted to show the prebiotic diet concept for
combating obesity by undertaking a similar comprehensive investigation, but utilized a
parallel design and a different kind of non-RS prebiotic diet. In that study, the changes in
the microbiota and some metabolites, although not including SCFA, were observed, but
without any concomitant improvement in metabolic functions [114]. This difference
could be due to RS4 having a different prebiotic impact on such parameters or due to the
crossover design of our study, which allowed each participant to serve as his/her own
control, minimizing the influence of confounding variables on treatment effects. In
addition, a stringent FDR at 0.05 helped minimize false positives for gut microbial
changes. Furthermore, novel associations among host metabolic functions and specieslevel composition of the gut microbiota were observed, many of which also coincided
with intra-species clustering, indicating the possibility of a synergistic (within bacterial
species) as well as super-system interactions (symbiotic host–microbe systems) linked
with metabolic functions. However, we note that fecal SCFAs represent <5% of the total
SCFAs that are typically excreted, while the major portion of SCFAs is efficiently
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absorbed in the intestinal lumen [103]. Also microbial communities in fecal samples may
potentially exclude gut residents that are not shed. Nevertheless, fecal specimens are the
most practical samples obtained from a human dietary intervention study for assessing
the gut microbiome.

2.6. Conclusion
In conclusion, this study provides evidence that dietary RS4 supplementation
selectively changes the gut microbial and metabolite environment as well as associated
host metabolic functions. To our knowledge, this is the first holistic study that
investigated the effects of the fermentable fiber, RS4, on the gut microbial ecology,
functional metabolites like SCFAs, and physiological responses in the host in one welldesigned study in a free living Caucasian cohort with signs of MetS. The findings support
the perceived role of the microbiota–host interaction in nutritional therapies with
important implications for dietary guidelines for individuals with metabolic disorders, a
major public health concern of the present day.

2.7. Future Directions
1. To compare the gut microbial profiles from persons with or without MetS, which
would help delineate the signature microbiome in MetS.
2. To identify the responders and non-responders to RS4 in terms of some selected
gut microbiota or SCFAs, or parameters.
3. To identify the sources of health promoting metabolites, either from food,
microbiota, or host itself.
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Figures and Legends

Figure 2.1. Study design
(a) Time line of the placebo-controlled, crossover, dietary intervention with resistant
starch (RS4) and control flour (CF). Stool and blood samples were collected before and
after each treatment period (indicated by arrows). (b) Trial profile and numbers of
participants in the study.
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Figure 2.2. Phylum-level gut microbial composition of participants at baseline
Mean percentage of total bacteria in the major phyla (n=19).
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Figure 2.3. Separation of the microbiome post intervention in RS4 and CF groups
Two-dimensional principal coordinate analyses (PCoA) based on the weighted UniFrac
distance between samples, given the abundance of 5,831 taxa present in at least one
sample (n=19). Axes 1 and 2 explain 26% and 13% of the variation, respectively (p =
0.01).
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Figure 2.4. Differential gut microbial composition after RS4 intervention at the
species level.
(a) Relative abundance of bacterial species (log10 fold change) in the RS4 group
compared with the CF group post intervention (n=19). Significant compositional
variation between the two groups before the intervention was previously ruled out. (b)
The Firmicutes/Bacteroidetes ratio after intervention (n=14). The dotted line represents
this ratio at baseline. (c) Abundance of major bacterial species (log10 fold change) before
and after RS4 treatment. #, the closest hit from the NCBI 16S rRNA database crossreferenced with the OTU from the Greengenes database. *Adjusted p (q)≤ 0.05, **q≤0.01,
***q≤0.001, § q≤0.09 (trend/approaching significance), n=19.
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Figure 2.5. Representative chromatograms showing the overlay of retention times of
butyl esters of SCFA fragment from standard and biological sample.
Butyl esters of acetic acid (1), propionic acid (2), iso-butyric acid (3), butyric acid (4),
iso-valeric acid (5), valeric acid (6), internal standard (7), and hxanoic acid (8). *
represents the di-butyl ether as a side product of butylation that did not co-elute with the
sample analytes. One of the collaborators, Dr. Ali Reza Fardin-Kia helped with technical
and instrumental aspects of GC-MS analyses.
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Figure 2.6. Effects of RS4 on fecal SCFAs
(a) SCFA abundance before and after RS4 intervention (*p≤0.05, n=19). (b) Positive
correlation of six bacterial species with increased SCFA levels in an RS4-specific manner
(p<0.05). Pearson coefficients are shown on heat map. #, the closest hit from the NCBI
16S rRNA database cross-referenced with the OTU from the Greengenes database. †,
species either significantly enriched or approached significance in the RS4 group. One of
the collaborators, Dr. Ali Reza Fardin-Kia and Robert Juenemann helped with technical
and instrumental aspects of GC-MS analyses.
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Figure 2.7. Associations between gut microbiota and host biological parameters
after RS4 and CF interventions
(a) Heat map showing Pearson’s r values (all, p<0.05). Black rectangular borders indicate
an association present only post RS4 intervention. #, the closest hit from the NCBI 16S
rRNA database cross-referenced with the OTU from the Greengenes database. †, species
either significantly enriched or approached significance in the RS4 group, n=15.
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Figure 2.8. Intra-associations within bacterial species that were correlated with
metabolic functions or SCFAs in an RS4-specific manner
Heat map showing Pearson’s r-values, corresponding to the size of the circle (n=19). The
black border indicates clustering of species (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, shown
only in the upper triangle). #, the closest hit from the NCBI 16S rRNA database crossreferenced with the OTU from the Greengenes database. †, species either significantly
enriched or approached significance in the RS4 group.
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Figure 2.9. Associations among host biological parameters in the RS4 group
Heat map showing Pearson’s r-values, corresponding to the size of the circle (n=13, *p ≤
0.05, **p ≤ 0.01, ***p ≤ 0.001).
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Table 2.1. Baseline characteristics of 20 participants
Criteria
Age (years)
<50
≥50

5
15

BMI
<30
≥30

5
15

Gender
Male
Female

8
12

Medication for
No medication
Type 2 diabetes
Heart diseases
Blood pressure
Fiber supplement
Probiotic
supplement
Digestive support
Cholesterol lowering
n: number of individuals
BMI: body mass index

n

8
4
2
11
2
1
3
5
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Table 2.2. Estimated nutrients intake at baseline and at the end of intervention
periodsa
Nutrients

BL

Post CF

Post RS4

Caloric intake (kcal/d)
Protein (g/d)
Carbohydrate (g/d)
Total fat (g/d)
Cholesterol (mg/d)
Saturated fat (g/d)
Monounsaturated fat (g/d)
Polyunsaturated fat (g/d)
Total dietary fiber (g/d)

1774±154
76±7
218±21
68±7
415±40
25±3
26±3
10±1
18±2

1528±121
72±5
220±19
60±5
442±38
22±2
22±2
9±1
16±2

1716±128
62±4
212±18
53±5
407±35
21±2
19±2
7±1
27±2

a

p: post CF
vs post RS4
NS
NS
NS
NS
NS
NS
NS
NS
<0.001

Data are Least Square Means+SEM adjusting for age, sex, season, colony and baseline
value analysed by linear mixed model; n=18-20 due to missing data points.
BL: baseline; CF: control flour; RS4: resistant starch type 4
One of the collaborators, Dr. Lacey McCormack helped with data analyses

50
Table 2.3. Means of biological parameters at baseline and at the end of intervention
periodsa

Anthropometrics
Weight (kg)
BMI (kg/m2)
Waist (cm)
Systolic BP (mm Hg)
Diastolic BP (mm
Hg)
% Body Fat
Fat-free mass (kg)
Glycemic Variables
(mg/dL)
Fasting glucose
Postprandial glucose
HbA1C (% of total
Hb)
Lipid Variables
(mg/dL)
Total cholesterol
HDL cholesterol
LDL cholesterol
NonHDL cholesterol
TC/HDL (ratio)
Triglyceridesb

BL

Post CF

Post RS4

p: Post
CF
vs Post
RS4

90.9±3.4
32.8±1.1
109.0±2.8
135.0±3.9
73.7±2.2

91.0±0.4
32.8±0.1
108.8±0.9
134.6±3.5
68.6±2.0

91.6±0.4
32.7±0.1
106.6±0.9
137.5±3.5
73.3±2.0

NS
NS
0.06
NS
NS

NS
NS
0.02
NS
NS

37.0±1.8
58.8±3.0

37.7±0.3
58.8±0.3

37.3±0.3
58.9±0.3

0.05
NS

NS
NS

106.5±4.1
113.5±11.8
5.89±0.3

111.5±4.2
124.3±7.3
5.81±0.1

101.9±4.3
114.3±7.5
5.75±0.1

0.09
NS
0.08

NS
NS
NS

196.6±11.6
43.6±3.3
122.7±10.1
153.1±11.8
5.0±0.5
161.5±19.9

192.8±4.6
44.1±1.3
117.4±5.6
148.4±4.6
4.7±0.2
144 (119176)

187.8± .9
39.8±1.3
118.0±6.1
147.5±4.9
5.1±0.2
138 (110173)

<0.001
<0.01
0.06
<0.01
NS
NS

0.01
0.001
0.06
0.03
NS
NS

p: BL
vs post
RS4

Blood Biomarkers
IL6 (pg/mL)
1.3±0.2
1.0±0.2
0.8±0.2
NS
0.04
TNF-α (pg/mL)
7.9±4.2
9.9±1.2
6.0±1.3
0.08
NS
10.8±0.4
10.0±0.4
0.02
<0.01
Adiponectin (µg/mL) 8.3±1.5
a
Data are Least Square Means+SEM adjusting for age, sex, season, colony and
baseline values.
b
Geometric mean and confidence interval are given for log-transformed
triglyceride endpoints.
One of the collaborators, Dr. Lacey McCormack helped with data analyses
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CHAPTER 3 . DIETARY RESISTANT STARCH TYPE 4-ASSOCIATED
BUTYRATE MODULATES LYSINE 27 TRIMETHYLATION OF HISTONE 3 IN
THE PROMOTER OF NUCLEAR FACTOR-KAPPA-B1 IN INTESTINAL
EPITHELIUM

Related publication: Liu, Y* and Upadhyaya, B*. et al. Dietary resistant starch type 4associated butyrate modulates lysine 27 trimethylation of histone 3 in the promoter of
nuclear factor-kappa-B1 in intestinal epithelium, Food & Function (2016) DOI:
10.1039/C6FO00856A [Accepted manuscript, *Equal contributors]

3.1. Abstract
Indigestible resistant starches (RS) are substrates for gut-microbial metabolism
and have been shown to attenuate intestinal inflammation but the supporting evidence is
inconsistent and lacks mechanistic explanation. We have recently reported dietary RS
type 4 (RS4) induced improvements in immunometabolic functions in humans and a
concomitant increase in butyrogenic gut-bacteria. Since inflammation is a key
component in metabolic diseases, here we investigated the effects of RS4-derived
butyrate on epigenetic repression of pro-inflammatory genes in vivo and in vitro. RS4-fed
mice, compared to the control-diet group, had higher cecal butyrate and increased trimethylation of lysine 27 on histone 3 (H3K27me3) in the promoter of nuclear factorkappa-B1 (NFκB1) in the intestinal tissue. The H3K27me3-enrichment inversely
correlated with concentration dependent down-regulation of NFκB1 in sodium butyrate
treated human intestinal cells. Two additional inflammatory genes were attenuated by
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sodium butyrate, but were not linked with H3K27me3 changes. This proof-of-concept
exploratory study presents a new opportunity for studying underlying H3K27me3 and
other methylation modifying mechanisms linked to RS4 biological activity.
Keywords: resistant starch type 4, sodium butyrate, H3K27me3, short chain fatty
acid, inflammation

3.2. Introduction
Intestinal gut microbiota utilizes prebiotic fibers like resistant starch (RS) as a
substrate to produce short chain fatty acids (SCFAs) that is proposed to play an antiinflammatory role in the maintenance of intestinal immune homeostasis [115], although
conflicting results exist [116]. Consumption of a fiber-rich diet is nevertheless considered
beneficial in several diseases such as obesity, inflammatory bowel disease, and metabolic
syndrome (MetS), all of which are associated with gut microbial dysbiosis and
dysregulated mucosal immunity [117]. In particular, inflammation is considered as a key
pathophysiological player in MetS [118]. We previously reported that consuming RS type
4-(RS4)-enriched flour (30% v/v) as part of a routine communal diet has significant
cholesterol lowering effects in healthy as well as in subjects with signs of MetS [25]. A
retrospective follow-up of the study showed that participants who consumed RS4 had
increased fecal SCFAs, particularly butyrate, in conjunction with increased butyrogenic
microbiota in fecal samples [119]. Butyrate, as a major and representative form of SCFAs,
has both trophic and bioactive functions on host cells by correcting the altered ratio of gut
bacteria and protecting against the potential pro-inflammatory molecules [35]. It has been
reported that increasing large-bowel butyrate supply has the potential to promote colonic
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integrity and lower colonocyte risk [120]. In that context this proof-of-concept study
aimed to explore if RS4 (chemically modified RS), particularly through butyrate
production, epigenetically regulates inflammatory gene expression in the gut.
Histone modifications, especially histone acetylation and methylation, play a
dominant role in epigenomic regulation of gene expression [121]. Butyrate is well known
as a histone deacetylase (HDAC) inhibitor that alters chromatin structure through histone
acetylation, which in turn affects target gene expression associated with the maintenance
of gut immune homeostasis [115, 122]. Butyrate’s anti-inflammatory activities [115]
result from both HDAC dependent and independent inhibition of transcription factor
nuclear factor kappa B (NFκB) [123, 124] as well as suppression of the downstream proinflammatory chemokines and cytokines [125, 126]. However, knowledge is limited
regarding the role of butyrate in modulation of histone tail methylation. Of particular
interest, in the context of inflammatory gene expression down-regulation, is the
trimethylation of H3 at lysine 27 (H3K27me3), an important and well-studied
modification that is frequently associated with transcriptional repression and gene
silencing [59, 127].
In the present study, the wheat-derived cross-linked RS4 is used which has been
thought to be effective in attenuation in postprandial glucose and insulin levels in humans
[72]. Since RS4 is insoluble, we first examined the in vitro effects of sodium butyrate
(NaBu) on H3K27me3 enrichment of gene promoters in conjunction with mRNA and
protein expression of selected inflammatory markers in a human intestinal epithelial cell
line, followed by a validation of RS4-induced butyrate production and a concomitant
H3K27me3 modifying effects in vivo in mouse colon tissue. Of the three selected
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inflammatory markers studied, a transcriptional factor NFκB1, which belongs to the
NFκB family of transcription factors, plays a central role in inflammatory signaling [128].
The remaining two inflammatory mediators represented a chemokine (C-C motif) ligand
2 (CCL2) that regulates migration and infiltration of monocytes/macrophages [125], and
a T-helper type 2 (Th-2) cytokine interleukin-10 (IL-10), which diminishes the activity of
Th-1 cytokine interferon gamma (IFNγ) and monocyte [126].

3.3. Materials and Methods
Materials
Dulbecco’s Modified Eagle’s Medium (DMEM) with 4 mM L-glutamine and 4.5
g/l glucose was purchased from HyClone (Logan, UT), fetal bovine serum (FBS), and
trypLE were purchased from Invitrogen Gibco (Grand Island, NY). Dimethyl sulphoxide
(DMSO), lipo-polysaccharide (LPS, from Escherichia coli, O55:B5),
penicillin/streptomycin, hydrogen chloride-1-butanol, and NaBu (sodium salt of butyrate)
were purchased from Sigma-Aldrich (St. Louis, MO), while IFNγ was purchased from
R&D Systems (McKinley, NB). For western blot, antibody against β-actin was purchased
from Santa Cruz Biotechnology (Santa Cruz, CA), antibody against NFκB1 was
purchased from Millipore (Billerica, MA), and Dylight 800 anti-rabbit secondary
antibody was purchased from Li-Cor Biosciences (Lincoln, NE). Anti-trimethyl-Histone
H3 Lys27 and rabbit IgG negative control antibodies used for chromatin immunoprecipitation (ChIP) assay were purchased from Upstate Biotechnology (Billerica, MA).
Enzymes used for ChIP assay, Micrococcal Nuclease (MNase) and Proteinase K were
purchased from Cell Signaling (Beverly, MA) and Pierce (Thermo Scientific, Rockford,
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IL), respectively. All other ChIP assay chemicals, aprotinin, DL-1, 4-Dithiothreitol
(DTT), Nonidet-P40 (NP-40) were purchased from Thermo Scientific (Rockford, IL),
while protein-A sepharose and sucrose were purchased from Sigma-Aldrich (St. Louis,
MO). ChIP incubation buffer was purchased from Abcam (Cambridge, MA) and DNA
purifying slurry for ChIP-graded DNA purification was purchased from Diagenode
(Denville, NJ). 2-Ethylbutyric acid ( 99%) and 1-butanol (99.9%) used as internal
standard in gas chromatography- mass spectrometry (GC-MS) were purchased from
Acros Organics (Mullica Hill, NJ) and Alfa Aesar (Ward Hill, MA), respectively. Hexane
(>97.0%) and sodium sulphate (granular, anhydrous, >99.0%) were purchased from
Fisher Scientific (Hampton, NH), while the inert helium gas was purchased from
Matheson (Sioux Falls, SD). Oligonucleotides were synthesized by IDT DNA Inc.
(Coralville, IA).

Cell culture and treatment
All in vitro assays were conducted in human colon cancer cell line, SW480 (CCL228, ATCC, Manassas, VA). Cells were grown in DMEM supplemented with 10% FBS,
1% penicillin (25 U/ml)/streptomycin (25 µg/ml) in a 95% air/5% CO2-humidified
atmosphere at 37 0C. This cell line was cultured as previously described [59]. Briefly,
SW480 cells were pre-treated with IFNγ (10 ng/ml) or control medium for 12 h, treated
with NaBu or DMEM (as a negative control) for 5 h and then stimulated with LPS (10
ng/ml) for 4 h. For every experiment, one positive control (cells treated with LPS) and
one negative control (cells treated without LPS or any NaBu treatments) were included.
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Two replicates were used for both the treatments and controls. LPS and NaBu were
reconstituted in DMEM.

Total RNA extraction, cDNA synthesis and quantitative polymerase chain reaction
(qPCR)
Total RNA was extracted from cells using TRIzol reagent (Invitrogen, Grand
Island, NY), following the manufacturer's instructions. RNA was quantified
spectrophotometrically by absorption measurements at 260 nm and 280 nm using the
NanoDrop system (NanoDrop Technologies, Wilmington, DE). RNA was then treated
with DNase I (Invitrogen, Grand Island, NY), following the manufacturer's guidelines to
remove any traces of DNA contamination. The cDNAs were synthesized using 3 µg of
RNA for each sample using the High-Capacity cDNA Reverse Transcription (RT) Kit
(Invitrogen, Grand Island, NY), following the manufacturers’ protocol. Two microliters
of each diluted sample was added to 0.5 µl of gene-specific primers and 12.5 µl of Power
SYBR green PCR master mix (Invitrogen, Grand Island, NY), and the final volume was
brought to 25 µl by adding sterile distilled water. PCR amplifications were performed on
a MX3005P system (Stratagene, San Diego, CA) using one cycle at 50 0C for 2 min, one
cycle of 95 0C for 10 min, 40 cycles of 15 s at 95 0C and 1 min at 60 0C, and the last cycle
with 95 0C for 1 min, 55 0C for 30 s, and 95 0C for 30 s. RNA extraction, purification,
cDNA synthesis and RT-PCR were performed as previously described [129] in duplicate.
Gene-specific primers used in the current study are described in Table 1. Calculations of
relative gene expression levels were performed using the 2-

ΔΔ

Ct

method [130]. The mRNA

levels were normalized to a housekeeping gene, glyceraldehyde-3-phosphate
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dehydrogenase (GAPDH), and expressed as a fold change relative to positive-control
cells.

Western blot analysis
For immunoblot analyses, IFNγ-primed NaBu-treated human intestinal epithelial
cells were activated with LPS for 4 h and harvested using RIPA lysis buffer (20 mM TrisHCl pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium
deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4,
1 µg/ml leupeptin). The Pierce BCA Protein Assay kit (Thermo Scientific, Rockford, IL)
was used to determine protein concentration. Proteins (35-50 µg/lane) were separated by
12% SDS-PAGE and the products were electrotransferred to polyvinyldene difluoride
membranes (Thermo Scientific, Rockford, IL). The membranes were blocked with 5%
skim milk for 1 h, and incubated with primary antibodies at 4 0C overnight (NFκB
p105/p50). On the next day, membranes were incubated with Dylight 800 anti-rabbit
secondary antibody (Li-Cor Biosciences, Lincoln, NE) for 1 h, and washed 3 times in
PBS/T (0.1% Tween20 in PBS) all at room temperature. After rinsing in PBS/T, blots
were imaged and quantitatively analyzed using an Odyssey infrared imaging system (LiCor, Lincoln, NE). A loading control protein, β-actin, was used to calculate the relative
expression of NFκB p105 and p50 subunits.

Native ChIP assay in cell culture
ChIP assay was performed as we previously described [59]. Briefly, cells were
lysed by suspending in a sequence of lytic and purification buffers. DNA fragments of
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300-800 bp long were obtained by treating the nuclear pellet, obtained from lytic buffers,
with MNase (Cell Signaling, Beverly, MA) in digestion buffer for 6 min. DNA fragments
were immunoprecipitated with specific antibodies (anti-trimethyl-Histone H3 Lys27 and
rabbit IgG) at 4 0C overnight. Immunoprecipitated DNA fragments were extracted using
protein-A sepharose (Sigma-Aldrich, St. Louis, MO) and purified using DNA purifying
slurry (Diagenode, Denville, NJ). The amount of purified DNA was estimated by
nanodrop of 200 ng purified DNA template using SYBR green chemistry as described in
RT-qPCR quantification section. Promoter-specific primers used in the current study are
described in Table 1. Calculations are expressed as a percentage of the input DNA.

Animal housing, diet and tissue collection
All in vivo procedures were approved and conducted following the Institutional
Animal Care and Use Committee (IACUC) of South Dakota State University guidelines.
Six-week old male KK.Cg-Ay/a (Jackson Laboratories, Bar Harbor, ME) mice were
grouped at random to consume either RS4 or control diets. To avoid confounding effects
of sex on weight gain, which was a measurable outcome for the study, only male mice
were considered. Also, this study was conducted prior to the implementation of federal
policy for considering both male and female sexes in biomedical experiments (NOT-OD15-102). Mice were caged in groups of three in a laboratory animal facility at an ambient
temperature of 24-26 0C with 12-h light/dark cycle. During the first 3 weeks mice were
allowed to acclimatize while consuming standard rodent chow, LabDiet® 5001 (LabDiet,
St. Louis, MO). Animals were then switched to experimental diets (LabDiet, St. Louis,
MO) formulated based on AIN 93 [131] either with 20% RS4 or control diet (CD).
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Detailed composition of experimental diets is provided in Table 2. Mice were provided
the experimental diets and water ad libitum for 12 weeks. Following CO2 euthanasia,
colon tissues and cecum samples were immediately collected, snap frozen in liquid
nitrogen and stored at -80 0C until further use.

Determination of cecal weight and butyrate analyses
Cecal tissues were weighed and pooled together (>500 mg in total weight) to
represent one sample and vortexed for 1 min with 1 ml of internal standard (2ethylbutyric acid in 1-butanol, 0.25 mg/ml). 0.5 ml of hexane (organic solvent) and 2 ml
of HCl-1-butanol (derivatizing agent) were then added to each sample followed by an
additional 1 min vortexing and 5 min sonication prior to being purged with an inert
helium gas. The tubes were immediately closed and each sealed container was incubated
in water bath at 60 0C overnight in order to catalyze the derivatization of butyrate analyte.
Upon being cooled to room temperature, 1.5 ml of additional hexane and 15 ml of
deionized water were added. Samples were mixed by vortexing 1 min following each
addition and then centrifuged at 3000 g for 2 min. The top organic layer (~2 ml) was
transferred into a 5 ml graduated vial before blowing down with helium to one-fourth of
the volume, thereby increasing the final concentration of internal standard from 0.25
mg/ml to 1 mg/ml. Finally, each sample was transferred into a sampling vial containing a
150 µl insert and ~10 mg of anhydrous sodium sulphate was added to remove the water
content before running into the GC-MS.
SCFAs were derivatized to obtain the corresponding butyl-esters (SCFABE) prior
to their gas chromatography (Agilent 7890A, Agilent Technologies, Wilmington, DE)
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and mass spectrometry (5977A MSD, Agilent Technologies, Wilmington, DE, USA)
using HP-5MS UI capillary column (30 m x 0.25mm, 0.2 µm thickness, Agilent,
Wilmington, DE, USA). Using hydrogen as carrier gas at a constant flow of 1.9 mL/min,
a typical injection volume (1 µl) was injected in the split mode (1:10). The separation of
SCFABE was achieved using an oven temperature program as follow: initial elution
temperature of 55 0C for 4 min, an increase by 5 0C/min to 120 0C followed by 20 0C/min
to 220 0C for 10 min. The selective mass detector was operated in the ‘single ion
monitoring and scan’ (SIM/Scan) mode with the source temperature (150 0C) and the
electron energy (70 eV). The abundance of butyrate analyte was identified by acquiring
ions of a specific m/z value. Finally, the data were analyzed and expressed as a unit of
mg/g of cecal tissues used.

Native ChIP assay in mouse colon tissues
Colon tissues were collected from mice immediately after sacrifice, snap-frozen
in liquid nitrogen and stored at -80 0C. On the day of assay, around 0.2 g of colon tissues
were rinsed in cold PBS and homogenized on ice in a pre-chilled tube with 1 ml of icecold Buffer 1 (0.06 M KCL, 15 mM NaCl, 5 mM MgCl2, 15 mM Tris-HCl pH 7.4-7.6,
0.1 mM EGTA, 0.3 M sucrose, 180 µg aprotinin, 5 mM sodium butyrate, 0.1 mM PMSF,
0.5 mM DTT), until the homogenate was free of clumps. The homogenate was then
filtered through four layers of muslin cheesecloth, pre-autoclaved and pre-moistened with
Buffer 1. The filtered cells were treated in the same way as described in the Native ChIP
assay in cell culture section. Promoter methylation of genes of interest was determined in
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mice fed RS4 or CD. Promoter-specific primers used in the current study are described in
Table 1.

Statistical analysis
Data are expressed as mean ± SEM. One-way analysis of variance (ANOVA) was
used to determine the significance between groups followed by the post-ANOVA
Dunnett test. Intergroup comparisons in Western blot, ChIP assay in mouse colon tissues
and for SCFAs in mouse cecal tissues were determined using Student’s t-test. A bivariate
analysis was carried out using correlation coefficient method and presented as Pearson’s r.
The significance of each treatment was interpreted by comparison with the appropriate
control, as described under specific methods. Experiments were repeated at least three
times. A probability (p) value of 0.05 or less was considered to be significant.

3.4 Results
NaBu attenuates expression of inﬂammatory mediators in a concentration
dependent manner in intestinal epithelial cells
LPS stimulated the production of pro-inflammatory mediators in IFNγ-primed
human intestinal epithelial cells. In the cells treated with NaBu, compared to the positive
control cells treated with LPS alone, we observed a concentration-dependent mRNA
attenuation of CCL2 and NFκB1 (Figure 3.1a). The highest concentration of NaBu tested
(1.25 mM) showed the strongest attenuation, lowering the relative mRNA expression of
CCL2 and NFκB1 by 90% and 63%, respectively (both p < 0.001). We also observed the
similar effects in case of cytokine IL-10, where NaBu (1.25 mM) inhibited IL-10 mRNA
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by 78% (p < 0.001, Figure 3.1a). The untreated cells that served as negative control
showed the highest level of IL-10, indicating the potential anti-inflammatory role of IL10 in the absence of a strong immune challenge by LPS (Figure 3.1a). However, it is
possible that IL-10 gained a pro-inflammatory characteristics when primed with IFNγ
prior to LPS induction as was observed by Sharif et al [132] and hence subsequently
responded to NaBu in a similar manner to that of the other two pro-inflammatory
mediators. This point is further elaborated in the “discussion” section.

NaBu enriched H3K27me3 in the promoter of NFκB1in intestinal epithelial cells
For ChIP assay we chose the highest dose (1.25 mM) of NaBu due to its most
suppressive effects as observed for the gene expression data (Figure 3.1a). Compared
with a positive control (Figure 3.1b), we observed the enrichment of H3K27me3 on the
promoter region of NFκB1 (0.47 ± 0.23% vs 1.28 ± 0.08%, p < 0.05). The H3K27me3
enrichment pattern was not clear for the IL-10 promoter, possibly due to high intersample variation. For CCL2, a similar enrichment pattern to that of NFκB1 was absent,
indicating the possibility of another gene regulatory mechanism influencing its mRNA
downregulation (Figure 3.1a). Since CCL2 is a downstream effector of NFκB signaling
[133], it is possible that the mRNA suppression of CCL2 is due to inhibition of NFκB1.

Concentration-dependent suppression of NFκB1 protein and mRNA by NaBu
inversely correlated with concentration-dependent enrichment of H3K27me3 in the
NFκB1 promoter
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We further examined the concentration-dependent effects of NaBu on NFκB1
mRNA and protein downregulations simultaneously with the determination of a
concentration-dependent H3K27me3 enrichment on NFκB1 promoter region. As shown
in Figure 3.2a, the protein expression of p105 as well as the active p50 subunits of
NFκB1 showed a concentration-dependent attenuation (p < 0.05) in response to NaBu in
the IFNγ-primed and LPS-induced human intestinal epithelial cells. Interestingly, the
relative protein expressions of both the sub units dropped close to the level of the
negative control when treated with the 1.25 mM NaBu (p105: 0.77 ± 0.03 vs 0.81 ± 0.08
folds and p50: 0.53 ± 0.15 vs 0.41 ± 0.13 folds). The suppression of both the subunits
also negatively correlated with a simultaneous concentration-dependent upregulation of
H3K27me3 modifications on the promoter region of NFκB1 (Figures 3.2b and 3.2c)
(p105: Pearson’s r = -0.98, p = 0.022 and p50: Pearson’s r = -0.97, p = 0.025). Further,
NaBu-associated H3K27me3 enrichment of NFκB1 promoter also inversely correlated
with the relative NFκB1 mRNA expressions (Pearson’s r = -0.95, p = 0.045, Figures 3.1a,
3.2b, and 3.2c).

Body mass and food intake in mice study
We have previously reported that RS4-enriched diet may be effective for reducing
pathophysiological consequences in humans with MetS [25]. Since KK.Cg-Ay/a mice
develops hyperglycemia, hyperinsulinemia, glucose intolerance and obesity by eight
weeks of age, we in this study utilized KK.Cg-Ay/a mouse model to mimic age-related
MetS in humans [134], evaluating the effects of RS4 intake on butyrate production in the
cecum and butyrate-associated epigenetic regulation of inflammatory genes in the
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intestinal tissue. Since RS4 is a stealth ingredient [135], we incorporated RS4 in the
mouse chow (20% v/v) and adjusted the CD to make it isocaloric with the addition of
cellulose (Table 3.2). At the end of the 12-week feeding study, the cumulative food
intake in RS4 group was around 35% higher when compared to that of CD group (560 ±
22 g vs 415 ± 26 g, p = 0.004, Figure 3.3a). However, the cumulative body weight
increases in both groups were similar during the 12-week period (Figure 3.3b),
suggesting a possible higher metabolic efficiency of RS4 diet than that of the control diet.

Cecal butyrate increased after RS4 intake in mice (butyrogenic effect of RS4)
We have observed increased fecal butyrate levels post RS4 consumption in
humans with MetS [119], which was expected due to RS4 being a non-digestible
fermentable fiber [25]. However fecal SCFAs represent <5% of the total SCFAs while
the majority of SCFAs are efficiently absorbed in the intestinal lumen [103]. In contrast,
the cecum butyrate concentrations from a MetS mouse model may represent a higher
proportion of the SCFAs produced in the gut. The mice group receiving RS4 showed a
trend for higher cecal weight compared to that of the CD group (322 ± 76 mg vs 135 ± 5
mg, p = 0.07, Figure 3.4a), which is in line with a previous report where fermentation of
RS type 2 and RS type 3 increased the cecal weight in mice [136]. Using these cecal
samples, GC-MS analyses showed that butyrate concentration was about two-fold higher
(0.81 ± 0.12 mg/g vs 0.39 ± 0.05 mg/g, p = 0.036) in the RS4 group than the CD group
(Figure 3.4a).
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Dietary RS4 intake enriched H3K27me3 in the promoter region of NFκB1 in mouse
intestinal tissue
After observing NaBu-mediated inhibition of histone modifications in vitro, we
sought to examine the similar effects in the colon tissue from KK.Cg-Ay/a mice fed with
20% RS4 for 12 weeks. ChIP assay revealed enrichment of H3K27me3 modification on
the promoter region of NFκB1 (1.4 fold, p = 0.01) after RS4 intervention compared with
CD (Figure 3.4b). This result supports the concept that feeding a butyrogenic dietary
fermentable fiber, such as RS4, enriches the epigenetic repressive mark (H3K27me3),
potentially contributing to the amelioration of the gut inflammation, a key factor
underlying many chronic disorders including MetS.

3.5. Discussion
Supplementation of diets with prebiotic fibers for potential mitigation of proinflammatory state in the context of chronic diseases, is an attractive area in public health
research [117]. It was particularly proposed that the inhibition of inflammatory
mediators through dietary enhancement of intestinal butyrate production has tremendous
implications in the context of managing obesity-related metabolic diseases [137]. To our
knowledge, this is the first report that dietary RS4 induced promoter-specific changes in
the H3K27me3 enrichment in vivo likely by the way of increased colonic butyrate
production. The in vitro observations further confirmed a concentration dependent
repression of both NFκB1 mRNA and protein levels in response to NaBu with a
concomitant enrichment in H3K27me3 levels.
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Dietary fibers, which are otherwise indigestible to humans, undergo microbial
fermentation in the hind-gut, particularly in the colon [138]. The colon is considered a
metabolic organ where the mucosal epithelia absorb topical nutrients, such as SCFAs
which play an important role in modulating gut immune system [139]. The gut
microbiota is an essential component in the colonic microenvironment and an altered gut
microbial composition or dysbiosis plays a critical role in the pathogenesis of intestinal as
well as extra-intestinal diseases [140]. Butyrate acts as an energy source by epithelial
cells [35] and inhibits genetic mutation [120] and oncogenic microRNA expression [141]
in rectal biopsies associated diet-induced manipulation. In addition, in vivo research has
investigated the anti-inflammatory role of SCFAs in regulating colonic regulatory T cells
(cTReg cells) in mice [142, 143]. Butyrate increases the expression of FOXP3, a
transcription factor functioning in intestinal inflammation, by increasing activity of
histone acetylation in its promoter and enhancer region [142, 144] and consequences
downregulation of pro-inflammatory mediators [145]. As we [119] and others [24] have
observed that RS4 mediates the modulation of butyrogenic gut microbiota, we
hypothesized that the observed immunomodulatory effects of RS4 in humans are at least
partially derived from the anti-inflammatory mechanisms of butyrate that is produced
after microbial fermentation of the dietary RS4. To minimize use of animals, we first
examined our hypothesis in an in vitro setting using a human intestinal cell line but since
RS4 is insoluble [28, 146], we used sodium butyrate for the in vitro tests.
The cytokine IL-10 is predominantly anti-inﬂammatory in nature that suppresses
the dendritic and macrophage cell functions [147]. The IL-10 may, however, acquire proinﬂammatory properties in inflammatory settings like endotoxemia, autoimmune diseases,
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and graft transplantations [148-150]. The balance between pro- and anti-inﬂammatory
activities of IL-10 is regulated by type I IFN [132]. Priming with type I IFNs (IFNα or
IFNβ ) also leads to enhanced cellular responsiveness to IFNγ [151], the latter acting as
an enhancer of cellular responsiveness to LPS through the toll-like receptor 4 signaling
pathway in human intestinal epithelial cells, including SW480 [152]. Therefore, in our
study, it is possible that IL-10 showed a pro-inflammatory nature as the human intestinal
epithelial cells were primed with IFNγ (10 ng/ mL) and stimulated with the LPS (10 ng/
ml), following Suzuki et al. [152]. Our results are also in line with the report of Saemann
et al. that showed NaBu exerts its IL-10 enhancing properties only under the dose of 0.25
mM, while inhibits IL-10 beyond the concentration of 0.25 mM [153]. This finding
further supports our observation of IL-10 inhibition by NaBu at the concentration range
of 0.31 to 1.25 mM. Also of interest is that the normal physiologic level of SCFAs in
portal blood is (0.38 ± 0.07 mM) [154], signifying the concentrations used in our study
are likely within the physiologically relevant range.
Although congenic, age-matched, and randomized mice were supplied with
isocaloric control diet, the cumulative food intake was consistently higher in the RS4
group. It is possible that palatability of RS4 and cellulose were different with RS4,
imparting minimal alteration of the physicochemical and organoleptic properties of the
final food products [28], the mouse chow in this case. Interestingly, in spite of higher
food intake, but with expected similar basal metabolic rate and physical activity, the mice
in the RS4 group did not have a significantly higher weight gain by the end of twelfth
week. This is consistent with the previous findings by Gao et al., [27] where butyrate
supplemented mice consumed higher feed intake and showed higher lean mass but lower
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fat mass, thus preventing diet-induced insulin resistance and obesity through more energy
expenditure. This is the limitation of our study that we could not examine the body mass
composition in the mice under study. In addition, the dietary fibers may also slow down
the digestibility of protein and fats in diets, thereby decreasing the metabolizable energy
content [155]. Since we also previously reported that RS4 consumption improves body
composition of humans [25], the current study further corroborates the previous findings
in KK.Cg-Ay/a mice and supports the suitability of this mouse model for age-related
MetS in humans as proposed by Kennedy et al [134].
The novelty of this research lies in the investigation of epigenetic mechanisms of
butyrate on H3K27me3-enrichment that inversely correlated with concentration
dependent down-regulation of a transcription factor NFκB1, which elegantly
substantiates our previous findings of health promoting [25] and butyrogenic effects of
RS4 [119]. Hence, RS4 and its derivative, butyrate, possesses promising clinical
implications in the management of cardio-metabolic diseases in humans.

3.6. Conclusions
This exploratory study introduces a proof-of-concept that RS4 and its bacterial
fermentation metabolite, butyrate, may function as an H3K27me3 modulator in
conjunction with its suppressive effects on NFκB1 in the intestinal cells in the context of
metabolic syndrome. Further characterization of prebiotic functional fibers-associated
epigenetic alterations may provide effective strategies to mitigate the low-grade
inflammation in the context of intestinal as well as extra-intestinal diseases associated
with dysbiosis.
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3.7. Future Directions
1. To include more of epigenetic marks, including both repressive and expressive
marks, on more pro-inflammatory and anti-inflammatory mediators.
2. To expand this colon cancer cell model into other disease models
3. To precisely measure the metabolic efficiency of mice fed with RS4 so that we could
explain why higher feed intake of RS4 did not result in to high weight gain.
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Figures and Legends

Figure 3.1. Effects of NaBu on inflammatory gene expression in human intestinal
epithelial cells
(a) Concentration-dependent mRNA expression of inflammatory genes relative to a
housekeeping gene, GAPDH. Values are expressed as mean ± SEM (n = 6), ***p <
0.001 compared with LPS treated (10 ng/ml) positive control. (b) Histone 3 lysine 27 trimethylation (H3K27me3) changes at promoter regions of inflammatory genes in cells
treated with 1.25 mM NaBu for 5 h. Average percentage input ± SEM from each
experiment (n ≥ 3) is plotted. *p < 0.05 compared with LPS treated positive control cells.
Dr. Yi Liu helped with this figure.
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Figure 3.2. Concentration-dependent effects of NaBu on NFκB1 in human intestinal
epithelial cells.
(a) Representative immunoblots showing the suppression of total cellular NFκB1
subunits p105 and p50. Densitometric analyses showing relative protein expressions
normalized to β-actin proteins and expressed as mean ± SEM (n = 3). *p < 0.05,
compared with LPS (10 ng/mL) treated positive control. (b) Histone 3 lysine 27 trimethylation (H3K27me3) changes at promoter regions of NFκB1 in cells treated with
different concentrations (0.31 to 1.25 mM) of NaBu for 5 h. Data points represent the
input ± SEM (n ≥ 4). *p < 0.05, compared with LPS control. Dr. Yi Liu helped partly
with this figure.
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Figure 3.3. Effects of RS4 on feed intake and body weight in KK.Cg- Ay/a mice
Cumulative food intake (a) and cumulative body weight gain (b) over a 12-week period
in six-week old KK.Cg-Ay/a mice fed with 20% RS4 (resistant starch) or control diet.
Data points represent the mean ± SEM (n = 3), *p < 0.05, **p < 0.01. Dr. Yi Liu helped
with this figure.
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Figure 3.4. Effects of RS4 on mice cecal weight, butyric acid levels and histone
modification
(a) Butyrate concentration (primary Y-axis on the left) per gram of cecal tissue
(secondary Y-axis on the right) taken from KK.Cg-Ay/a mice after 12 week of feeding
RS4 (20%) or control diet. Data represent the mean ± SEM (n = 3), *p < 0.05. (b) Dietinduced differential tri-methylated histone 3 modifications on lysine 27 (H3K27me3) at
promoter regions NFκB1 in the colon tissues of KK.Cg-Ay/a mice fed with either RS4
(resistant starch, 20%) or control diet for 12 weeks. Average percentage input ± SEM
from each experiment (n = 3) is plotted, **p < 0.01. Dr. Yi Liu helped partly with this
figure.
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Table 3.1. Primer sequences used for qRT PCR and ChIP assays
Gene

qRT PCR (SW480 cells)

ChIP Assay (SW480 cells)/
(Mice tissue)

CCL2

IL-10

NFκB1

F: 5’-agtctctgccgcccttct-3’

F: 5’-gtggtcagtctgggcttaatg-3’

R: 5’-gtgactggggcattgattg-3’

R: 5’-ctgctgagaccaaatgagca-3’

F: 5’-cataaattagaggtctccaaaatcg-3’

F: 5’-aaggccaatttaatccaaggtt-3’

R: 5’-aaggggctgggtcagctat-3’

R: 5’-tttggtttcctcaccctactgt-3’

F: 5’-accctgaccttgcctatttg-3’

F: 5’-ttggcaaaccccaaagag-3’/
F: 5’-cgatctgagtgtagccgaga-3’

R: 5’-agctctttttcccgatctcc-3’

R: 5’-ggtttcccacgatcgattt-3’/
R: 5’-gctgggcacaaaagtcaatc-3’

GAPDH F: 5’-agccacatcgctcagacac-3’
R: 5’-gcccaatacgaccaaatcc-3’
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Table 3.2. Composition of experimental diets per 100 grams
Ingredients

Control Diet

RS4 Diet

Midsol TM 501

31.77

27.07

Fibersym RW2

0.00

23.5

Powdered cellulose

18.80

0.00

Casein – vitamin free

14.00

14.00

Dextrin

13.67

13.67

Sucrose

8.82

8.82

Soybean oil

8.00

8.00

AIN 93M mineral mix

3.50

3.50

AIN 93M vitamin mix

1.00

1.00

Choline Bitartrate

0.25

0.25

L-Cystine

0.18

0.18

t-Butylhyrdoquinone

0.0008

0.0008

1

Midsol TM 50 is wheat starch with energy content 359.5 Kcal/100 g.
Fibersym RW is resistant starch type 4 (85%, dry basis) with energy content 56.5
Kcal/100 g
2
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CHAPTER 4 . MATERNAL HIGH-FAT DIET AND GESTATIONAL DIABETES
AFFECT HISTONE MODIFICATIONS ON CARDIO-METABOLIC GENE
PROMOTERS IN OFFSPRING

Related publication: Upadhyaya, B. et al. Maternal high-fat diet and gestational diabetes
affect histone modifications on cardio-metabolic gene promoters in offspring (2016) [In
preparation]

4.1. Abstract
A nutrient-mediated fetal metabolic programming in utero due to maternal highfat (HF) diet and gestational diabetes mellitus (GDM) increases the risk of the adult-onset
of obesity, type 2 diabetes mellitus, and cardiovascular disease (CVD) in offspring.
However, the precise mechanism of excess circulatory lipids in cardiac tissue-specific
epigenetic programming remains poorly understood. In this pilot study, we seek to
investigate a genome-wide chromatin landscape due to histone modifications (H3Ac,
H3K4me3, and H3K27me3) in rat offspring heart tissue in response to either maternal HF
(40% kcal) diet or streptozotocin-induced GDM, or both using a previously validated rat
model. We observed that gestational diabetes was associated with cardiac hypertrophy
(p<0.05). Chromatin immunoprecipitation sequencing of offspring’s heart tissue revealed
the differential peaks distribution (FDR<0.1) due to Ac, H3K4me3 and H3K27me3
histone modifications on the promoter regions mapped to rat genome. Downstream gene
ontology analyses showed that out of 28 annotated genes, supposedly expressed
(H3K4me3 gained peaks, FDR<0.1) in high fat-diet group, 15 genes were 1) annotated to
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“metabolic process” in general and “positive regulation of cholesterol biosynthetic
process” (FDR=0.0295) in particular; 2) overlapped with a total of 455 quantitative trait
loci (QTL), primarily consisting of 66 QTL for blood pressure (19.34%), 24 QTL for
body weight (5.27%), and 20 QTL for serum cholesterol (4.40%); 3) related to
susceptibility or disease progression to several CVDs revealed through disease ontology
analyses. Together, these findings show that maternal HF with or without GDM changes
the cardiac epigenetic signature through histone modifications in rat offspring. This
differential fuel-mediated epigenetic programming help assess the risks for obesity,
diabetes, and CVDs beyond one generation, potentially leading to novel preventive and
treatment strategies.
Keywords: Cardiovascular disease, ChIP sequencing, developmental programing,
gestational diabetes, histone modifications, maternal high-fat diet

4.2. Introduction
Gestational diabetes mellitus (GDM), one of the most common complications in
pregnancy, occurs when hyperglycemia (> 92−125 mg/dL, fasting glucose) associated
glucose intolerance is first diagnosed at any time of pregnancy, or in between 24 and 28
weeks in particular [41]. 17.8% (9.3-25.5%) of overall pregnancies in the US are affected
by GDM [42] and its occurrence parallels to the increasing obesity epidemics [39], which
shows 34.4% of US women are obese in their child-bearing stage [40]. In addition to
well-known risk factor of genetic susceptibility, over nutrition of the fetus in utero is
another critical factor to shape the metabolic profile of offspring for the rest of their life
[43, 44]. Siblings born to a diabetic mother possess a significantly higher risk of
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developing diabetes later in life than in those born to the same mother before being
diagnosed with diabetes [156]. Similarly, embryo transfer experiments in rats [157]
further provided compelling evidence to support that adult metabolic consequences are
caused by the diabetic environment in utero.
The food plan that tightly controls the blood glucose level is often the first
recommended strategy to manage GDM. However, the problems may arise when dietary
carbohydrates go down (from ~60% to ~40%) and the compensatory fats usually go up
(from ~20% to ~40%) [45] in order to meet the caloric needs of a rapidly growing fetus.
Since heart constantly demands a high-energy source to maintain its contractile activity
that requires a turnover of entire ATP pool in every 10 seconds, it has the ability to utilize
all fuel sources including fatty acids, which indeed is the primary energy source for the
normal adult heart [46]. Hence, the quantity as well as quality of the dietary fat during
pregnancy plays a major role in cardiometabolic health outcomes in offspring above and
beyond the pregnant mother [47]. Offspring of obese or diabetic mother have significant
risk of cardiovascular diseases (CVD) at birth [158, 159] and throughout the life [160].
Interestingly, since studies show that many women even with good glycemic control have
infants with CVD [159, 161], mechanistic research, which links adult nutrigenomic
consequences to fuel-mediated fetal programming due to exposure of excess circulatory
lipids in utero [162], are critically needed especially in combination with GDM.
It has recently become apparent that posttranslational modification (PTM), which
may be epigenetically inherited, are involved in gene expression or repression during
developmental nutritional programing [163]. DNA methylation and histone modification,
two major types of epigenetic marks that also crosstalk with each other, lead to a stable
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long-term gene repression and a reversible short-term gene expression/repression,
respectively [164]. These modifications alter gene expression by changing the
conformation of the chromatin states into open or closed, hence modulating the
accessibility of the promoter regions, upstream to the transcription start site, to bind with
transcription factors and RNA Polymerase II before the gene transcription starts [165].
Only a few studies show maternal HF diet during pregnancy regulates rat offspring’s
gene expression through histone modifications in liver-specific manner [166-168].
However, the genome-wide chromatin landscape in rat offspring heart tissue in response
to maternal obesity and diabetes in pregnancy remains unknown.
Since we already reported that a maternal HF diet further impairs cardiac
functions due to lipid droplet accumulation, metabolic disturbances, oxidative stress, and
mitochondrial dysfunction in rat offspring born to diabetic dams [169], this follow-up
(proof-of-concept) study seek to investigate three most widely studied histone PTMs,
namely acetylated histone 3 (H3Ac, a gene activation mark), trimethylated lysine at
position 4 of histone 3 (H3K4me3, a gene activation mark), and trimethylated lysine at
position 27 of histone (H3K27me3, a gene repression mark), following prenatal exposure
to maternal HF diet and late gestation diabetes, either individually or in combination,
using the previously validated rat model.

4.3 Methods
Animal study and dietary intervention
Female Sprague-Dawley rats (Harlan Laboratories Inc., Indianapolis, IN) were
fed either control diet (TD2018 Teklad, Harlan Laboratories, Madison, WI)) or high-fat
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diet (TD95217 custom diet Teklad, Harlan Laboratories, Madison, WI) for at least 28
days prior to breeding and throughout the pregnancy (Figure 4.1), following the
guidelines of Institutional Animal Care and Use Committee at Sanford Research. All rats
were housed in a temperature-controlled, light-dark cycled facility with water and chow
supplied ad libitum. 18% and 40% of calories came from saturated and monounsaturated
fat content in case of control diet (CD) and high-fat diet (HF), respectively, as we
recently reported [169]. To induce gestational diabetes on day 14, pregnant dams were
injected intraperitoneally either with 65mg/kg of streptozotocin (STZ, Sigma Life
Sciences, St. Louis, MO) or 0.09 M citrate buffer (CB) as a placebo. Maternal late
gestation blood glucose levels were monitored twice daily by tail nick sampling to a One
Touch Ultra meter (LifeScan Inc., Milpitas, CA). The offspring were delivered normally
on gestation day 22. Finally, neonate rat hearts from 4 different groups- CD with CB
(CC), CD with STZ (CS), HF with CB (HC), and HF with STZ (HS)- were collected and
snap-frozen after euthanizing the rat pups soon after the delivery.

Chromatin immunoprecipitation (ChIP) assay
Five to six frozen heart tissues were pooled to make >250mg/sample and
homogenized followed by chromatin isolation using P-2001 ChromaFlashTM Chromatin
Extraction Kit (Epigentek, Farmingdale, NY). Chromatin was sheared using
Episonic2000 Sonication System (Epigentek, Farmingdale, NY) in 300 µl of ChIP buffer,
followed by a quality control of sheared chromatin using fluorescence quantification. 4 µl
of sheared chromatin was purified to obtain DNA, which was eluted with 20 µl of water.
DNA fragment (100-300 bp) was quality-checked using Bioanalyzer analysis. For each
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ChIP reaction, 10 µg of chromatin, 3 µg of H3K4me3 polyclonal antibody or 3 µg of
H3K27me3 antibody or 3 µg of H3 Acetyl polyclonal antibody (all from Epigentek,
Farmingdale, NY) and 6 µl of protein A/G beads were used. ChIPed DNA was eluted in
20 µl of water. The H3K4me3, H3K27me3 and H3 Acetyl antibodies were tested and
proven to be ChIP-grade.

ChiP sequencing and analyses
A ChIP-sequencing library was prepared using the EpiNext ChIP-Seq High
Sensitivity Kit with amplification, DNA end polishing and adaptor ligation, following the
manufacturer’s instruction. 10 nM of sample libraries were provided for next generation
sequencing on a HiSeq 2500. The basic analysis of ChIP-Seq was based on the published
protocol [170] utilizing Bowtie, version 1.0.0 [171] and MACS, version 2.1.0 [172]. Raw
reads were quality checked using FastQC, version v0.10.1 [173] and mapped onto the rat
RN5 genome sequence using Bowtie, version 1.0.0 [171]. The option of “-m 1” was
activated so that only uniquely mapped reads were allowed to map. The mapping results
in SAM were converted to BAM and sorted according to coordinates using samtools,
version 0.1.19 [174]. Mapping results of each ChIP sample and the input sample were
subjected to ChIP enriched peak calling. The option of “--broad” was activated to
optimize the calling algorithm for broad binding regions. The called peaks are annotated
to the nearest TSS (Transcript Starting Site) using ChIPpeakAnno, version 3.2.0 [175].
ChIP quality control was performed using ChIPQC, version 1.2.2 [176]. All raw and
processed sequencing data are deposited to NCBI GEO database under the accession
number GSE84831.
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Bioinformatics analyses
Enriched peaks were called and then annotated to the nearest transcription start
site of the genes. Peaks were visualized using Integrative Genomics Viewer (PMCID:
PMC3346182). Genomic distribution of peaks were summarized in a heat map using
Seqminer version 1.3.3 [177]. First, the genomic reference peak set
(TSS.rat.Rnor_5.0.bed) was imported. Then the mapping results (BAM) were loaded;
read densities were extracted and clustered (linear Kmeans clustering) using the default
parameters. Differential binding analyses was carried out to determine the differential
enrichment of cardiac-specific genes due to 4 different diet-conditions in all regions and
in promoter region only. Promoter regions were further validated by having CpG islands
using online database [178]. Likewise, a gene ontology analysis [179] was carried out to
determine which biological processes that were triggered by 4 different diet-conditions.
Enriched gene ontology analysis was carried out using online database GOEAST [180].
Rat genome database [181] was extensively used to annotate the gene, overlapping
quantitative trait loci (QTL) and disease ontologies.

Statistical analyses
Statistical analyses were performed with Sigma Plot (Systat Software, Inc. San
Jose, CA). To compare two diet-groups, a t-test was used. When the data were not normal,
a Mann-Whitney U test was used. Principal coordinate analysis was used to show the
difference among three histone modifications. The genome mapping statistics was
extracted using Picard, version 1.90 [182]. Differential binding analyses was carried out
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using a DiffBind Bioconductor R package [183]. Data were expressed as mean±SEM. A
value of p<0.05 or FDR<0.1 was considered significant.

4.4. Results
Maternal late gestation STZ-induced diabetes increases the offspring’s heart weight
To analyze the effects of maternal late gestational diabetes on the heart weight of
the offspring, we compared the average weight of the hearts obtained from the pups
whose mothers were fed either control diet (C) or high fat (H) diet with (CS and HS) or
without (CC and HC) streptozotocin (S)-induced diabetes. Pups from CS group had
significantly higher average heart weight compared to their control CC (55.64±1.95 mg
vs. 48.94±2.03 mg, p=0.030). A similar effect of STZ was observed in high fat diet-fed
mice groups combined with STZ (HS) when compared to diet-matched control group HC
(52.92±1.62 mg vs. 44.91±2.30 mg, p=0.013) (Figure 4.2a). In addition, pups from CS
group had higher heart to body weight ratio when compared to control CC group
(0.0089±0.0004 vs. 0.0071±0.0002, p=0.001). Although we observed the similar trend in
HS vs. HC groups, the heart to body weight ratio were not significantly different
(p=0.118). However, HS group had significantly higher heart to body weight ratio when
compared to the CC control group (0.0082±0.0003 vs. 0.0071±0.0002, p=0.006) (Figure
4.2b). Interestingly, these significantly higher heart weight in the offspring from the STZ
groups corresponded to a trend of elevated maternal late gestation glucose levels induced
by STZ when compared to CC and HC diet-matched control groups (305.30±92.01
mg/dL vs. 82.23±3.92 mg/dL and 295.42±39.27 mg/dL vs. 88.30±2.61 mg/dL,
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respectively) (Figure 4.2c). Taken together, gestational diabetes is related to enlargement
of offspring’s heart, perhaps due to fuel mediated energy homeostasis.

Differential histone modification profiles in cardiac tissue of offspring related to
maternal HF diet and GDM in pregnancy
Since we recently showed that the maternal high-fat diet alters the cardiac
functions in offspring of diabetic pregnancies [169], we further seek to investigate the
intergenerational effects of high-fat diet and gestational diabetes epigenetically through
histone modifications. Using ChIP-grade antibodies, ChIP assays followed by ChIP
sequencing revealed the differential peak distribution in offspring’s heart tissue due to Ac,
H3K4me3 and H3K27me3 modifications, which were responsive to control or HF diet
with or without STZ induction during pregnancies (Figure 4.3). A total of around 41000,
73000 and 54000 significant peaks (FDR<0.1) were observed due to H3Ac, H3K27me3
and H3K4me3 histone modifications, respectively, in control diet group. When we
mapped peaks to the rat genome, only 29%, 11% and 36% of the total peaks overlapped
to the known exonic regions (data not shown), which shows that most of H3K27me3
peaks occurred in non-exonic and gene regulatory elements. These differential histone
modification profiles were further validated with principal component analyses that
showed 24% and 20% of variations were explained by principal component axes 1 and 2,
respectively. Both being an expressive epigenetic mark, H3Ac and H3K4me3
modifications clustered together, separated from a repressive epigenetic mark,
H3K27me3 (Figure 4.4a). However, the effects of diet were not so distinct within each
category of histone modification. Since we carried out ChIP sequencing from the
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offspring’s’ heart whose mothers, not the offspring themselves, were fed a specific diet,
we observed only subtle differences in the genome wide histone marks for H3Ac,
H3K4me3, and H3K27me3 (Figure 4.4b). Interestingly, in 5kb upstream regions,
combination of diabetes and high fat diet in gestation (HS group) showed relatively
higher and lower mean densities (tag/50bp) than the individual ones (CS or HC alone) in
case of expressive marks (H3Ac and H3K4me3) and repressive mark (H3K27me3),
respectively (Figure 4.4c). Additionally, when we compared the different histone
modifications from a representative high fat-diet group, H3K4me3 showed a much higher
mean density that was slightly correlated (Pearson’s r=0.29) with another expressive
H3Ac mark but without any correlation (Pearson’s r=0.09) with a repressive H3K27me3
mark. Together, both the expressive histone marks, H3Ac and H3K4me3, functions
similarly, which is different to that of H3K27me3.

Diet-specific differential histone modifications in the gene promoter region
In order to locate the histone modifications in the annotated genomic region, ±
5kb distances to the nearest transcriptional start site (TSS) of genes annotated to rat
genome 5.0 were identified and plotted. Around 40% of all the peaks were enriched in
the upstream (- 5kb) of any known TSS, which was the consistent pattern for all four
diet-groups. In case of H3Ac modification, we observed a decrease in the total number
of peaks in 5kb upstream of any known TSS in diabetes-induced (CS group) by 52% and
in high fat diet-fed (HC group) by 53%. However, we found the opposite trend where CS
and HC groups had additional 33% and 73% of K4me3 specific peaks and 56% and 70%
of K27me3 specific peaks, respectively (Figure 4.5). Interestingly, K4me3 modification
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also showed that the high-fat and diabetes combined (HS group) had an additional 89%
of peaks when compared to the control (CC group), which is already 9.5% more than its
diet-matched control (HC group) (Figure 4.5). In case of H3Ac, differential binding
analyses (FDR< 0.1) revealed that CS and HC groups had two and three significantly lost
peaks, respectively, in 5kb upstream gene promoter region when both were compared to
CC group (Table 1). H3K27me3 showed a mixed response: six peaks were significantly
gained for each CS and HC group, while three and one peaks were significantly lost for
CS and HC groups, respectively (Table 4.1 and Table 4.2). However, two and 28 peaks
were significantly gained in CS and HC groups, respectively, when compared to CC
group in case of H3K4me3. Out of these 28 annotated genes supposedly expressed in
high fat-diet group, 15 genes were related to “metabolic process” in the gene ontology
category of biological process, validating the critical role of HF diet in GDM due to fetal
metabolic programming in utero.

Maternal high fat diet aggravates gestational diabetes that associates with metabolic
consequences in the offspring
Since both high fat diet and diabetes closely link to each other, we hypothesize a
common gene network regulating metabolic process. As expected, H3K4me3 enriched
two closely related genes, heat shock protein 1a1 (Hspa1a) and Hspa1b, were found to be
associated with of CS diet (6.54 fold, FDR=0.02) and HC diet (5.62 fold,
FDR<0.001)(Table 4.2). Remarkably, other maternal high-fat diet (HC group) induced
offspring’s H3K4me3 enriched genes were ATP synthase mitochondrial Fo complex,
subunit C3, subunit 9 (Atp5g3, 6.10 fold, FDR=0.07); Cytochrome P450, family 4,
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subfamily f, polypeptide 18 (Cyp4f18, 5.06 fold, FDR=0.01); autophagy associated
transmembrane protein (EI24, 2.79 fold, FDR=0.02); endoplasmic reticulum
oxidoreductase beta (Ero1lb, 6.66 fold, FDR=0.002); farnesyl diphosphate synthase
(Fdps, 1.9 fold, FDR=0.06); hexose-6-phosphate dehydrogenase (H6pd, 6.75 fold,
FDR<0.001); P450 (cytochrome) oxidoreductase (Por, 6.16 fold, FDR=0.06); solute
carrier family 11, member 2 (Slc11a2, 6.7 fold, FDR<0.001) and tripartite motif
containing 63, E3 ubiquitin protein ligase (Trim63, 4.99 fold, FDR<0.001).
On the other hand, since H3K27me3 is a repressive mark, we considered the loss
of peaks as a gain of gene function. We found several candidate genes on which
H3K27me3 peaks were significantly lost in HF diet combined with GDM (HS group)
when compared to GDM alone (CS group), suggesting the expression of those genes
associated to further metabolic stress and diabetes. These candidate genes included ATP
binding cassette subfamily B member 9 (Abcb9, 5.6 fold, FDR=0.02); Atp5g2 (5.92 fold,
FDR=0.003); lysine demethylase 6B (Kdm6b, 5.37 fold, FDR=0.08); LIM domain
binding 1 (Ldb1, 5.73 fold, FDR=0.01); nuclear receptor subfamily 4, group A, member
3 (Nr4a3), 3.41 fold, FDR=0.004); RuvB-like AAA ATPase 2 (Ruvbl2, 3.40 fold,
FDR=0.05); Solute carrier family 44, member 4 (Slc44a4, 6.17 fold, FDR<0.001); steroid
sulfatase (microsomal), isozyme S (Sts, 1.82 fold, FDR=0.08); urocortin 2 (Ucn2, 2.61
fold, FDR=0.06). Similarly, a significant gain of H3K27me3 peaks in two candidate
genes were supposed to be repressed in HS group when compared to CS group. These
candidate genes were adenylate kinase 3 (Ak3, 1.95 fold, FDR=0.09) and signal
transducer and activator of transcription 5B (Stat5b, 3.76 fold, FDR=0.09). Taken
together, maternal high fat diet not only shares with gestational diabetes some candidate
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genes that affect the metabolic consequences in the offspring but also aggravates the
gestational diabetes.

Maternal high fat diet and gestational diabetes affect the genes and QTLs related to
metabolic diseases in the offspring
Some of the gene ontologies related to mitochondrial function were enriched
among those 15 genes of interest in case of H3K4me3 due to high fat diet. Interestingly,
both diabetic diet (CS) and high-fat diet (HC) groups showed H3K4me3 peaks gain in
heat shock protein 1a and 1b in common. Enriched gene ontology analyses revealed that
both Hspa1a and Hspa1b were enriched for “primary metabolic process” in HF-induced
H3K4me3 modification (log2 odd ratio 1. 38, FDR=0.06) (Table 3). Moreover, enriched
gene ontology of “positive regulation of cholesterol biosynthetic process” (FDR=0.0295)
was associated to farnesyl diphospho synthase (Fdps) and P450 (cytochrome)
oxidoreductase (Por) (Table 4.3 and Supplementary Table 4.1). Despite the genes of
interest belong to different chromosomes or genomic regions, we found that those 15
genes overlap with a total of 455 QTLs, primarily consisting of 66 QTLs for blood
pressure (19.34%), 24 QTLs for body weight (5.27%), and 20 QTLs for serum
cholesterol (4.40%)(Table 4). Particularly, Fdps overlapped with a total of 33 QTLs, out
of which 22 QTLs (66.67%) were related to blood pressure. Atp5g3 overlapped with a
total of 22 QTLs, out of which 9 QTLs (40.91%) were related to body weight. Similarly,
Por and Ero1lb overlapped with a total of 12 and 19 QTLs, respectively, out of which 2
(16.67%) and 3 (15.79%) QTLs, respectively, were related to serum cholesterol (Table
4.4, suggesting the putative role of HF diet in hypercholesterolemia. Furthermore, disease
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ontology revealed that Hspa1a gene was related to the disease progression of systolic
heart failure and other cardiovascular diseases like coronary disease, atherosclerosis, and
acute coronary syndrome. Hspa1b, a close relative of Hspa1a, was related to obesity,
type 2 diabetes mellitus, and hyperlipidemia. H6PD was related to experimental diabetes
mellitus and inborn errors on metabolism, further supporting the role of HF diet either
alone or in combination with GDM on the fetal metabolic programming of adult-onset
diabetes and cardiovascular diseases.

4.5. Discussion
A successful pregnancy should primarily be defined not only by the outcome at
birth but also by the health status in later life [44]. A growing number of animal models
and human epidemiological studies have shown that fetal metabolic programming play a
crucial role in perpetuating the vicious cycle of cardiometabolic conditions through one
generation to the other [184] but the molecular mechanisms remain poorly understood.
To this context, we previously reported that maternal HF diet (40% kcal from fat)
aggravates the gestational diabetes through lipid droplet accumulation, metabolic
abnormalities, oxidative stress, and mitochondrial dysfunction in a rat model [169]. To
our knowledge, this follow-up study is the first to further explain the heart tissue-specific
epigenetic marks in the rat offspring born to diabetic and obese pregnancy, utilizing a
genome-wide ChIP sequencing.
Using a rat model of gestational diabetes with or without maternal obesity [169],
we introduced STZ-induced diabetes in pregnant rats at gestational day 14 (Figure 4.1),
simulating GDM in humans that occurs in third-trimester of pregnancy [41]. This is
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appropriate because the late GDM is less likely associated with congenital heart, which
mostly occurs in early pregnancy [185, 186], minimizing the confounding cardiovascular
outcomes due to maternal diet. HF diet, the second half of the intervention in this study,
included more saturated (~13% kcal from fat) and monounsaturated (~17% kcal from fat)
fatty acids but with similar polyunsaturated fatty acids (~8% kcal from fat) when
compared to CD diet, showing a translational or feasible diet choice for typical
Americans [187]. More recently paternal diet has also been shown to play a key role in
the metabolic programming of the offspring [188]. In our study, female rats were bred
with normal control diet-fed males, ruling out the possible effects of the paternal diet on
the observed outcomes.
The fuel-mediated teratogenesis hypothesis shows the association between
maternal hyperglycemia in pregnancy and obesity or cardiovascular complications in
fetus [156]. In our study, late gestational maternal glucose was elevated, as expected,
after STZ-induced diabetes (Figure 4.2c). However, the concomitant high level of
maternal insulin that we previously observed [169] cannot freely cross the placenta to the
fetus [189]. Therefore, in order to respond to this high glucose load the developing fetal
pancreas produces additional insulin, causing fetal hyperinsulinemia as we and others
previously reported [169, 190]. Interestingly, insulin resistance, a biomarker of type 2
diabetes, has also been associated with altered cardiac singling and the development of
hypertension-associated left ventricular hypertrophy [190, 191]. This aligns with our
observation that weight of the offspring hearts (Fig 2a) and heart to body ratio (Figure
4.2b) were significantly higher in STZ-induced diabetic group (CS) when compared to
control group (CC).
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Since histone modification, mostly of short-term and reversible in nature, usually
precedes the DNA methylation that facilitates a long-term gene repression [164], here in
this proof-of-concept study we focused only few well-studied representative histone
marks: H3Ac, H3K4me3, and H3K27me3 using a validated ChIP-grade antibodies.
These choices were based on the proposal that developmental specification is
accompanied by a striking transition form a permissive chromatin state with widespread
remodeling to a restrictive state with pervasive Polycomb repression [192]. Broadly, the
oxidative stress-mediated regulation cascade is the common mechanistic link among the
pathogenesis of diabetes, hypertension, and other related inflammatory diseases [193]. In
our study, several H3K4me3 peaks, which are the gene activating marks, were
differentially gained in the promoter regions of genes pertaining to metabolic stress
regulation, including Atp5g3 associated with mitochondrial injury [194], Ei24 reported to
have an effect on autophagy [195], H6pd associated with fuel metabolism and
experimental diabetes mellitus [196], Erol1b associated with decrease insulin synthesis
leading to diabetes mellitus [197], SLC11A2 increased with body fatness [198], CYP4F
associated with oxidation of inflammatory lipid substrates [199], and Trim63 associated
with several human heart conditions, such as hypertrophic cardiomyopathy and chronic
heart failure [200].
Notably, Hspa1a and Hspa1b were the common candidate genes in HF and CS
treated groups, showing a degree of common pathways of obesity and diabetes. Indeed,
increased Hspa1a is not only linked with HF-associated oxidative stress in metabolic
syndrome patients [201] but also correlates with HbA1c values in women with GDM
[202]. This could be the reason why our disease ontology analyses linked Hsp1a1 and
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Hspa1b with severe disease progression to systolic heart failure [203] and CVD [204].
Furthermore, Por and Fdps showed enriched “metabolic process” gene ontology in
general and “positive regulation of cholesterol biosynthesis process” in particular (Table
3). Por is associated with microsomal P450s-mediated xenobiotic metabolism as well as
cholesterol and bile acid synthesis [205], while Fdps is associated with cholesterol
biosynthesis and hypercholesterolemia [206]. Interestingly, all of these annotated genes
overlapped with “blood pressure” QTLs while most of them overlapped with “cholesterol
synthesis” QTLs, which clearly demonstrates that the epigenetic cues already in place at
birth affect the adult-onset diseases like atherosclerosis, hypertension, and CVD. These
results further corroborate our previous findings that HF diet in GDM causes oxidative
stress and mitochondrial dysfunction [169].
Since H3k4me3 (active) and H3K27me3 (inactive) modifications co-exist to form
bivalent promoters in early life, promoters quickly respond to the developmental stimuli
and change their histone modification state mainly through H3K27me3 demethylation
[207]. Interestingly, when we compared the effects of HF diet on diabetic background
(HS vs. CS groups), a lysine demethylase enzyme, Kdm6b, was associated with a
significant H3K27me3 loss [208]. This suggests that several candidate genes with
H3K27Me3, including Kdm6b, were likely upregulated when HF diet is provided in
GDM. To this context, our candidate genes, ABCB9 (associated with type 2 diabetes
[209]; ATP5G2 (associated with insulin secretion [210]; Ldb1 [211], NR4A3 [212] and
SLC44A4 [213](all associated with β-cell and pancreatic islets functions); RUVBL2
(associated with insulin-stimulated GLUT4 translocation [214]; Sts (associated with HF
diet and ob/ob models of obesity and type 2 diabetes [215]; and Ucn2 (associated with
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heart failure patients [216], lost a repressive H3K27me3 mark and were likely expressed.
Interestingly, in case of H3K27me3 peaks gain in the promoter regions of AK3
(associated with downregulation of insulin secretion [217]) and STAT5B (associated with
negative regulation in adipogenesis [218] further validated the HF-induced gene
repression of AK3 and STAT5B, leading to more insulin secretion and adipogenesis.
Hence, epigenetic processes represent a central underlying mechanism of
developmental programming of T2D and CVD [219]. In a similar study to ours, rat adult
offspring, exposed to a maternal HF diet in utero, at 6 months of age showed
significantly higher body weights, greater adiposity, and increased triacylglycerol levels
than that of control rats in spite of their similar weights at birth [220]. To this context, we
also expect that it might take a longer time to manifest more phenotypic outcomes
because there were no significant differences in the birth weights observed among
offspring in different groups (data not shown). Indeed, we have already collected heart
tissues of the weaned pups (3 weeks age) and adult rats (12 weeks age) from the same
breeding mates kept in the same diet groups. Due to limited resources, only the neonatal
hearts were analyzed for ChIP sequencing to report in this pilot study. Our prospective
and comprehensive longitudinal study will also encompass whether the effects of postnatal dietary habits at different life stage of the offspring can alter the epigenetic
landscape set at the birth, making them either less or more prone to adult-onset CVD.
Since the fetal primordial germ cells, that determines the fate of F2 generation is also
likely affected by intrauterine environment [219], studies highlighting the importance of
HF diet and GDM in the context of intergenerational and transgenerational (F3
generation and beyond) metabolic programming [221] above and beyond the first
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generation is imperative. Moreover, considering the gender-specific fetal response to the
same environmental insults due to maternal as well as paternal diet would reveal more
information on differential metabolic profiles due to sexual dimorphism and genomic
imprinting. Besides, the functional microarray or RNA Seq would allow us to delineate
the functionality of epigenetic marks annotated to the nearest transcription start sites.
Therefore, characterizing these altered epigenetic marks at-birth by taking the surrogate
tissues like placenta and cord blood with a minimal invasive technique could function as
the first-step in developing a clinical biomarker based on the intra-uterine environment,
which merits further study on screening the fetus at an increased risk of adult-onset
chronic diseases.

4.6. Conclusion
This follow-up study of fuel-mediated cardiac dysfunction in offspring [169] is
the first to further explain the role of maternal HF diet on heart tissue-specific differential
histone modifications (H3Ac, H3K4me3, H3K27me3) in the rat offspring born to obese
and/or diabetic pregnancy, utilizing a genome-wide ChIP sequencing and bioinformatics
analyses. Identification of this reversible epigenetic landscape in utero and its association
to risks for adult-onset of chronic CVDs provides an effective strategy for novel cardiometabolic health management in next generation and future generation
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4.7. Future Directions
1. To carry out ChIP sequencing and RNA sequencing on the same tissue so that the
histone modifications and putative functionality can be compared at the same
time.
2. To carry out ChIP sequencing of heart tissues collected from different age groups
(e.g., 3 weeks or 12 weeks in rats) so that the changing epigenetic landscape can
be monitored.
3. To carry out transgenerational metabolic programming study that involves

feeding of mother or father or both and observing the epigenetic effects in 3 or
more generations to come.
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Figures and Legends

Figure 4.1: Study timeline
Female Sprague-Dawley rats were randomized into four groups and fed high fat diet (HF)
or control diet (CD) for 28 days prior to their breeding and throughout the pregnancy. On
gestational day 14, each HF or CD group was treated with intraperitoneal injection of
Streptozocin (STZ, 65 mg/Kg) or citrate buffer (CB) as a control. Pups were normally
delivered on gestational day 21 and sacrificed for their hearts collection. One of our
collaborators, Dr. Michelle Baack developed and carried out the rat model used in this
study.

Figure 4.2: Physiological characteristics pups and their dams under study
Bar graphs showing the higher neonatal heart weight (a) and neonatal heart to body
weight ratio (b) that corresponds to elevated maternal late gestation glucose levels (c) in
Streptozotocin-induced diabetes groups. n= 10-12 (a and b), n= 2 (c). *p<0.05, **p<0.01,
***p<0.001 (t-test). CC, controls; CS, diabetes induced; HC, high-fat diet fed; HS, highfat fed and diabetes induced. One of our collaborators, Dr. Michelle Baack analyzed the
characteristics of dams and pups under study.
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Figure 4.3: Peaks detection in ChIP sequencing
Representative genomic region of a negative strand (chromosome 7) near the
transcriptional start site of Atp5g2 gene, illustrating 5kb upstream peaks in cyan
(acetalyation), red (H3K427me3), blue (H3K4me3), and grey (Input control) colors. CC,
controls; CS, diabetes induced; HC, high-fat diet fed; HS, high-fat fed and diabetes
induced.
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a

Figure 4.4: Differential histone modification profiles
a) Principal component analyses showing different profiles among three histone
modifications. Axes 1 and 2 possess 24 and 20% of variations, respectively. b) Genome
wide differential histone marks in H3Ac, H3K4me3 and H3K27me3 modifications due to
different diets. Read density in +/- 5 kb of any known transcriptional start site for each
marker are clustered and visualized in a heat map, each of which consists of four panels
in the order of CC (control), CS (diabetes-induced), HC (high fat diet-fed), and HS
(combined HC and CS) from left to right. From the vertical view, clusters with the central
density profile are located at the top, followed by clusters with peaks in the -5 kb region
(marked under the black lines), those with peaks in the +5 kb region, those with diffuse
read density, and those without significant read density. c) Corresponding mean density
(tag/50bp) plots for H3Ac, H3K4me3 and H3K27me3 modifications in +/- 5 kb of any
known transcriptional start site due to different diets.
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Figure 4.5. Peaks overlapping any 5kb upstream region of known exons
For each histone modifications of H3Ac (Ac), H3K4me3 (K4) and H3K27me3 (K27),
peaks with 5kb upstream of any known TSS are counted and plotted as indicated. CC,
controls; CS, diabetes induced; HC, high-fat diet fed; HS, high-fat fed and diabetes
induced
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Table 4.1. Diet-specific differential binding of peaks in respective histone
modification in genomic and 5kb upstream region
CC vs CS
(gained/lost peaks)
Histone
Modification All
Promoter
region
Region

CC vs HC
(gained/lost peaks)
All
Promoter
region
Region

CS vs HS
(gained/lost peaks)
All
Promoter
region
Region

H3Ac

0/32

0/2

5/103

0/3

0/0

0/0

H3K4me3

8/6

2/0

449/11

28/0

1/6

1/0

H3K27me3

186/82

6/3

309/114

6/1

403/226

4/22

CC, controls; CS, diabetes induced; HC, high-fat diet fed; HS, high-fat fed and diabetes
induced
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Table 4.2. List of “metabolic process” candidate genes with differentially bound
peaks
Modificati
on

Diets

Genes

Ensemble ID

Fold

FDR

H3Ac

CC vs CS

Myrf

ENSRNOG00000028274

-5.53

1.59E-02

H3K4me3

CC vs CS

Hspa1a

ENSRNOG00000050647

6.54

2.49E-02

Hspa1b

ENSRNOG00000050647

6.54

2.49E-02

Atp5g3

ENSRNOG00000001596

6.10

7.63E-02

Cyp4f18

ENSRNOG00000015751

5.06

1.27E-02

Ei24

ENSRNOG00000030391

2.79

2.42E-02

Ero1lb

ENSRNOG00000002609

6.66

1.96E-03

Fdps

ENSRNOG00000043377

1.92

5.66E-02

H6pd

ENSRNOG00000017523

6.75

7.39E-04

Hspa1a

ENSRNOG00000050647

5.62

3.76E-05

Hspa1b

ENSRNOG00000050647

5.62

3.76E-05

Mapk8ip2

ENSRNOG00000032828

6.16

6.08E-02

Napsa

ENSRNOG00000019854

6.18

5.66E-02

Nfix

ENSRNOG00000002983

2.09

8.40E-02

Por

ENSRNOG00000001442

6.16

6.08E-02

Slc11a2

ENSRNOG00000019550

6.73

9.55E-04

Trim63

ENSRNOG00000016543

5.00

9.51E-04

Zim1

ENSRNOG00000015071

6.28

3.43E-02

Bmp8b

ENSRNOG00000033209

2.25

3.03E-02

Gli1

ENSRNOG00000025120

2.77

6.51E-02

Rps29

ENSRNOG00000032542

3.73

7.29E-02

Snapc3

ENSRNOG00000010825

4.51

7.29E-02

Ccdc126

ENSRNOG00000009322

-4.10

9.17E-02

Dstyk

ENSRNOG00000021298

2.57

8.56E-02

Lhpp

ENSRNOG00000017097

5.63

1.69E-02

CC vs HC

H3K27me3

CC vs CS

CC vs HC
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CS vs HS

Zfp444

ENSRNOG00000015517

-5.83

4.77E-02

Ak3

ENSRNOG00000015273

1.95

9.12E-02

Stat5b

ENSRNOG00000019075

3.76

8.66E-02

Abcb9

ENSRNOG00000001082

-5.60

2.22E-02

Atp5g2

ENSRNOG00000015320

-5.92

3.41E-03

B3gnt3

ENSRNOG00000018764

-5.79

7.71E-03

Kdm6b

ENSRNOG00000037613

-5.37

7.80E-02

Ldb1

ENSRNOG00000018468

-5.73

1.10E-02

Metap1

ENSRNOG00000012947

-5.58

2.46E-02

Nfic

ENSRNOG00000004505

-4.58

3.65E-03

Nr4a3

ENSRNOG00000005964

-3.41

3.70E-03

Ruvbl2

ENSRNOG00000020793

-3.40

5.43E-02

Slc44a4

ENSRNOG00000000878

-6.18

2.79E-04

Snapc3

ENSRNOG00000010825

-4.17

4.90E-02

Sts

ENSRNOG00000032487

-1.82

7.95E-02

Ucn2

ENSRNOG00000020655

-2.61

5.70E-02

Uqcrq

ENSRNOG00000048174

-5.73

1.10E-02

CC, controls; CS, diabetes induced; HC, high-fat diet fed; HS, high-fat fed and diabetes
induced
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Table 4.3. List of “metabolic process” candidate genes (high fat diet) with gene
ontology enrichment
Gene

Enriched GO
ID

Description of GO

Log2
Odd
Ratio

FDR

Atp5g3

GO:1901360

Organic cyclic compound metabolic process

1.96

0.0976

GO:0044238

Primary metabolic process

1.38

0.0636

GO:1901360

Organic cyclic compound metabolic process

1.96

0.0976

GO:0044248

Cellular catabolic process

2.87

0.0976

GO:0044238

Primary metabolic process

1.38

0.0636

GO:0016709

Oxidoreductase activity

6.13

0.0976

Ei24

GO:0030308

Negative regulation of cell growth

4.80

0.0726

Fdps

GO:0045542

Positive regulation of cholesterol biosynthetic
process

8.68

0.0195

GO:1901360

Organic cyclic compound metabolic process

1.96

0.0976

GO:0044238

Primary metabolic process

1.38

0.0636

GO:1901360

Organic cyclic compound metabolic process

1.96

0.0976

GO:0044238

Primary metabolic process

1.38

0.0636

GO:0008180

COP9 signalosome

6.31

0.0976

GO:1901360

Organic cyclic compound metabolic process

1.96

0.0976

GO:0044248

Cellular catabolic process

2.87

0.0976

GO:0090083

Regulation of inclusion body assembly

8.09

0.0312

GO:0044238

Primary metabolic process

1.38

0.0636

GO:0008180

COP9 signalosome

6.31

0.0976

GO:0043281

Regulation of cysteine-type endopeptidase
activity involved in apoptotic process

4.43

0.0976

GO:1901360

Organic cyclic compound metabolic process

1.96

0.0976

GO:0044248

Cellular catabolic process

2.87

0.0976

GO:0090083

Regulation of inclusion body assembly

8.09

0.0312

GO:0044238

Primary metabolic process

1.38

0.0636

Cyp4f18

H6pd

Hspa1a

Hspa1b
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Mapk8ip2

GO:0044238

Primary metabolic process

1.38

0.0636

Napsa

GO:0044238

Primary metabolic process

1.38

0.0636

Nfix

GO:1901360

Organic cyclic compound metabolic process

1.96

0.0976

GO:0044238

Primary metabolic process

1.38

0.0636

GO:0045542

Positive regulation of cholesterol biosynthetic
process

8.68

0.0195

GO:0043281

Regulation of cysteine-type endopeptidase
activity involved in apoptotic process

4.43

0.0976

GO:0044248

Cellular catabolic process

2.87

0.0976

GO:0044238

Primary metabolic process

1.38

0.0636

GO:0016709

Oxidoreductase activity

6.13

0.0976

GO:0043281

Regulation of cysteine-type endopeptidase
activity involved in apoptotic process

4.43

0.0976

GO:1901360

Organic cyclic compound metabolic process

1.96

0.0976

GO:0044238

Primary metabolic process

1.38

0.0636

GO:0044248

Cellular catabolic process

2.87

0.0976

GO:0044238

Primary metabolic process

1.38

0.0636

Por

Slc11a2

Trim63
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Table 4.4. Metabolic process candidate QTLs obtained from the candidate genes
(high fat diet specific)
QTL Count (Percent Total)

Gene

Cyp4f18

Ei24

Ero1lb

Fdps

H6pd

Hspa1a

Hspa1b

Mapk8ip2

Napsa

Body
Weight

Glucose
Level

Insulin
Level

Insulin
Dependent
Diabetes
Mellitus

Non-insulin
Dependent
Diabetes
Mellitus

Serum
Cholesterol

88

24

7

5

4

15

20

(19.34%)

(5.27%)

(1.54%)

(1.10%)

(0.88%)

(3.30%)

(4.40%)

7

9

1

1

(31.82%)

(40.91%)

(4.55%)

(4.55%)

3

3

2

1

1

(21.43%

(21.43%)

(14.29%)

(7.14%)

(7.14%)

QTL
Total
455

Atp5g3

Blood
Pressure

22

14

19

19

33

12

3

3

12

16

7

2

1

2

2

(36.84%)

(10.53%)

(5.26%)

(10.53%)

(10.53%)

7

1

2

1

2

3

(36.84%)

(5.26%)

(10.53%)

(5.26%)

(10.53%)

(15.79%)

22

3

2

(66.67%)

(9.09%)

(6.06%)

7

2

(58.33%)

(16.67%)

1

1

1

(33.33%)

(33.33%)

(33.33%)

1

1

1

(33.33%)

(33.33%)

(33.33%)

6

1

2

1

(50.00%)

(8.33%)

(16.67%)

(8.33%)

7

1

1

2

2

(43.75%)

(6.25%)

(6.25%)

(12.50%)

(12.50%)
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Nfix

Por

Slc11a2

Trim63

Zim1

4

12

8

19

6

1

1

(25.00%)

(25.00%)

6

1

1

1

1

2

(50.00%)

(8.33%)

(8.33%)

(8.33%)

(8.33%)

(16.67%)

5

1

(62.50%)

(12.50%)

7

3

1

4

(36.84%)

(15.79%)

(5.26%)

(21.05%)

1

2

1

1

(16.67%)

(33.33%)

(16.67%)

(16.67%)
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CHAPTER 5 . PHENETHYL ISOTHIOCYANATE INHIBITS ALDEHYDE
DEHYDROGENASE ACTIVITY AND TARGETS REACTIVE OXYGEN
SPECIES-MEDIATED APOPTOSIS IN HUMAN CANCER STEM CELLS

Related publications:
Wang, D., Upadhyaya, B. et al. Phenethyl isothiocyanate upregulates death
receptors 4 and 5 and inhibits proliferation in human cancer stem-like cells BMC Cancer
2014 14:591[Equal first author]
Upadhyaya, B. et al. Phenethyl isothiocyanate inhibits aldehyde dehydrogenase
activity and targets reactive oxygen species-mediated apoptosis in human cancer stem
cells (2016) [In preparation].

5.1. Abstract
Aldehyde dehydrogenase family 1 (ALDH1) is a cancer stem cell (CSC) marker
that associates with tumor malignancy and self-renewal properties of stem cells in
different tumors. Tumor cells also have higher load of oxidative stress than normal cells
where as cancer stem cells (CSCs) are more stable because of the redox balance
machinery. Mounting evidence has supported that further exposure of reactive oxygen
species (ROS)-load will exhaust their antioxidant potential and induce even more
apoptosis in CSCs compared to cancer cells. However, how phenethyl isothiocyanate
(PEITC), a prooxidant and an inhibitor of liver ALDH2, selectively targets cervical CSCs
has remained unknown. Hence, we seek to investigate whether PEITC could inhibit
ALDH1 and cell proliferation and induce ROS in HeLa CSCs (hCSCs). Results showed
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that sphere-culture method significantly enriched CSCs from HeLa cells (p<0.05). Flow
cytometry revealed that PEITC attenuated ALDHhi cells in hCSCs (p<0.05). ROS assay
showed that PEITC induced oxidative stress in hCSCs, which was glutathione dependent.
PEITC also inhibited a transcription factor Sp1 and multidrug resistance protein, Pglycoprotein in hCSCs (p<0.05). Xenotransplantation study in a non-obese diabetic,
severe combined immunodeficient (NOD/SCID) mouse model and histopathology
showed anti-tumorogenic and anti-metastatic potential of PEITC in vivo. Taken together,
this proof-of-concept study showed that PEITC effectively targets multi-drug resistant
and metastatic hCSCs through inhibition of ALDH enzyme and Sp1 transcription factor
and induction of oxidative stress and apoptosis in cervical hCSCs. Therefore, PEITC
commonly found in cruciferous vegetables may offer a novel approach to target CSCs for
improving therapeutic outcomes in cancer patients.
Key words: ALDH, cancer stem cells, oxidative stress, phenethyl isothiocyanate,
Sp1 protein

5.2. Introduction
Cancer stem cells (CSCs), a subset of cancer cells (0.1- 30%) with self-renewal
and differentiation potential, have been implicated in tumor initiation, maintenance,
metastasis, and recurrence of a number of cancer types [50, 51]. Survival of CSCs from
chemo or radiotherapy include expression of drug efflux transporters, expression of antiapoptotic proteins, enhanced activity of repair enzyme, hypoxic stability, vascular niche,
and dormancy [51]. To identify and isolate CSCs from within a heterogeneous population
of cancer cells, several CSC putative surface markers have been proposed, such as
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CD133+, CD24- and CD44+, that often associate with aggressive cancer types and poor
prognosis [222, 223]. Recent studies have also shown that aldehyde dehydrogenase
family 1 (ALDH1) is a CSC marker that associates with tumor malignancy and selfrenewal properties of stem cells in different tumors, including breast [52], head and neck
[224], melanoma [225], hepatic [226], pancreatic [227], colon [53], lung [228], prostrate
[229], bladder [230] ovarian [231], endometrial [232] and cervical [54, 55] cancers.
Hence, CSCs-targeted therapy is of growing interest and concern given the fact
that conventional chemo or radiotherapy cannot and does not eradicate the drug-resistant
CSCs [51]. This is due to the activity of drug efflux transporter proteins or ATP binding
cassette (ABC) transporters, such as P-glycoprotein (P-gp), breast cancer resistance
protein (BCRP) and multidrug resistance-associated proteins (MRP), which usually
overexpress in drug-resistant CSCs [233]. Particularly, P-gp having a broad substrate
specificity is considered as a main impeding factor in the anticancer therapy [234]. Since
P-gp protein is mediated through expression of MDR1 gene, activation of MDR1
promoter region gets activated with specificity protein (Sp1) [235]. Sp1 being a
ubiquitous transcription factor for Sp1-regulated genes involved in cell proliferation and
cancer development [236], there is a need of anti-cancer compound that does not easily
get excreted out of the cell and target Sp proteins in CSCs.
Besides drug-resistance potential, CSCs possess another survival machinery of
enhanced redox homeostasis. Due to increased oxidative metabolism and shortage of
nutrient supply rapidly growing cancer cells have higher levels of reactive oxygen species
(ROS) than normal healthy cells [237]. Hence, one established strategy to induce
apoptosis and kill only cancer cells is to further increase the ROS levels, since the
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threshold to resist elevated ROS levels is usually low in cancer cells when compared to
normal cells. However, the challenges arise due to the fact that the CSCs possess lower
redox stress due to high levels of anti-oxidant machineries [238], such as glutathione
(GSH) and lipid peroxidation enzyme, aldehyde dehydrogenase (ALDH). ALDH
enzymes irreversibly catalyze the oxidation of aldehydes to their respective carboxylic
acids, thereby reducing the cellular oxidative stress [239]. Therefore, to exploit the
similar effect of elevated ROS in CSCs, naturally occurring pro-oxidant dietary
compounds is essential because of their no side effects even in the high doses.
Phenethyl isothiocyanate (PEITC) is a biologically active dietary compound present in
cruciferous vegetables, including watercress, broccoli, cabbage, and cauliflower [56,
240]. Others and we have previously reported the anti-inflammatory [57, 58] and chemopreventive characteristics of PEITC against various cancers [59, 61, 240]. Because of its
non-toxicity [63] and high efficacy among other isothiocyanates (ITCs) [241] PEITC is
currently under phase II clinical trials for lung cancer (NCT00691132). PEITC depletes
GSH and selectively inhibits proliferation of cancer cells due to elevated ROSaccumulation inside the cells [242, 243]. Interestingly, PEITC also inhibits liver ALDH
enzyme in the context of ethanol administration in rats [244]. However, the pro-oxidant
effect of PEITC in inhibiting ALDH1 in the context of CSCs and more specifically
cervical CSCs is entirely unknown.
Apoptosis, or programmed cell-death, is essential to maintaining tissue
homeostasis, and its impairment is implicated in many human diseases, including cancers
[245]. Since we recently showed that PEITC targets CSCs through apoptosis [61], in this
study we hypothesized that PEITC induces ROS-mediated apoptosis in CSCs and inhibits
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a CSC marker ALDH1 and drug efflux transporter protein P-gp, using a cervical cancer
HeLa sphere culture model in vitro and non-obese diabetic/ severe combined immune
deficit (NOD/SCID) mouse model in vivo.

5.3. Materials and Methods
Sphere cultures of hCSCs
Following our previous work [61], human cervical HeLa cell line (CCL-2,
American Type Culture Collection, Manassas, VA) was cultured and maintained in a T25 flask with Dulbecco’s modified eagle’s medium (DMEM) containing 4 mM Lglutamine and 4.5 g/L glucose (HyClone, Logan, UT), supplemented with 10% heatinactivated fetal bovine serum (Invitrogen, Grand Island, NY) and 1% penicillin (25
U/ml)/streptomycin (25 µg/ml) (Sigma-Aldrich, St. Louis, MO) in a 5% CO2-humidified
atmosphere at 37°C. HeLa cells were trypsinized with TrypLE (Invitrogen, Grand Island,
NY) and then sub-cultured with a 1:5 splitting ratio when the cells reached about 90%
confluency. From the parental HeLa cells CSCs (termed simply as hCSCs in the rest of
the document) were cultured following a modified protocol described by Gu et al. [246].
Briefly, single-cell suspensions of HeLa cells (4×104) were seeded into a 100-mm ultralow attachment (ULA) petri dish (Corning Inc., Corning, NY) containing 8 ml of serumfree mammary epithelial basal medium (MEBM, Lonza, Allendale, NJ), supplemented
with 1x B27 (Invitrogen, Grand Island, NY), 4 µg/ml heparin (Sigma-Aldrich, St. Louis,
MO), 20 ng/ml hEGF, and 20 ng/ml hFGF (Invitrogen, Grand Island, NY). After an
initial 5-day culture in suspension at 37 °C, an additional 9 ml of sphere culture medium
was added for another 5 days of culture. On day 10, spheres were harvested by
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centrifugation at 500 x g for 3 minutes, followed by washing with phosphate-buffered
saline (PBS), trypsinization with TrypLE for 10 minutes at 37 °C, centrifugation at 500 x
g for 3 minutes, resuspension in 5 ml of hCSC culture medium, and counting with a
hemocytometer. Both HeLa cells and hCSCs were used for flow cytometry experiments.

Aldefluor assay
The Aldelfluor Kit (STEMCELL Technologies, Vancouver, Canada) was used to
determine the enzymatic activity of ALDH in HeLa and hCSCs. hCSCs were treated with
PEITC (Sigma-Aldrich, St. Louis, MO) or dimethyl sulfoxide (DMSO, Sigma-Aldrich,
St. Louis, MO) 24 hr prior to cell harvesting. Cells were trypsinized, washed with 1x
PBS, and counted using a hemocytometer. Cells were then resuspended in Aldefluor
buffer at a concentration of 2 × 105 cells/mL. Activated Aldefluor reagent (300 µM) was
prepared following the manufacturer’s instructions. PEITC Cells were incubated with
activated Aldefluor reagent and its control reagent, diethylaminobenzaldehyde (DEAB) at
37°C for 45 min, with intermittent shaking after every 15 min. Following incubation, all
the tubes were centrifuged at 250 x g for 5 min at 4oC. Aldefuour-stained cells were
washed once in Aldefluor buffer, and maintained in 4°C until acquired through FL1
channel in flow cytometer (FACSCalibur, Becton, Dickinson and Company, San Jose,
CA) as ALDH high and side scatter low phenotypes.

ROS assay
Cells were harvested, trypsinized, washed with 1x PBS, and counted using a
hemocytometer before collecting in conical test tube. Using Cellular ROS Detection
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Assay Kit (Abcam, San Fransisco, CA), the cells were stained with 20 µM 2’, 7’ –
dichlorofluorescin diacetate (DCFDA) in 1X Buffer supplied for 30 minutes at 37 °C
following the manufacturer’s protocol. 2 x 105 hCSCs per sample were aliquoted into a
six-well plate and incubated with 10 µM PEITC or DMSO control for 3, 6, or 9 hr at 37
°C. GSH (Sigma-Aldrich, St. Louis, MO) was used as an inhibitor of the ROS production
and a pro-oxidant hydrogen peroxide (H2O2) was used as a positive control in the assay.
The read signal was detected at Ex485 nm/Em535 nm using a flow cyotometer.

Flow cytometry
Cells were washed with 2 ml of PBS, trypsinized with 1 ml of TrypLE, and
resuspended in 1 ml of PBS, followed by immunostaining. Similarly, hCSCs were
collected after 10 days of culture, trypsinized, and resuspended in 2 ml of PBS with a
density of 1×106 cells/ml, followed by immunostaining. Cells were immunostained with
anti-CD24–FITC (1:500 v/v, Millipore, Billerica, MA) or anti-CD44–FITC (1:500 v/v,
Millipore, Billerica, MA) antibodies for 1 hour at room temperature.
Immunofluorescence was measured using FACSCalibur cell analyzer (Becton Dickinson,
San Jose, CA) with approximately 10,000 events in each sample. Propidium
iodide/annexin V staining was performed according to the manufacturer’s instructions.
Briefly, 5×105 cells were centrifuged and resuspended in 100 µl of 1x binding buffer
(Invitrogen, Grand Island, NY). The cells were treated with 10 µM PEITC or vector
control (DMSO) for a total of 24 h. The cells were then incubated with 5 µl of annexin
V–FITC (eBioscience, Inc., San Diego, CA) and 5 µl of propidium iodide (eBioscience,
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Inc., San Diego, CA) at room temperature for 5 minutes in the dark before acquiring at
least 10,000 cells in a flow cytometer.

Sphere-formation assay
The hCSCs were enriched in spheres in serum-free medium. Sphere culture was
carried out as previously described in the sphere culture section. Cells were treated with
predetermined doses of 2.5, 5 or 10 µM of PEITC or DMSO as control. After 7 days
incubation, photomicrographs of spheres were acquired under an inverted phase-contrast
microscope (Olympus America Inc., Center Valley, PA), and the number of hCSCs was
counted using a hemocytometer.

Cell proliferation assay
A standard colorimetric method (MTS assay) was used to determine the number
of viable cells, which were harvested and counted with a hemocytometer before seeding
into 96-well microplates at a density of 2×104 cells per well. Cells were cultured in
DMEM supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, 5% heatinactivated FBS, and 50 µM 2-mercaptoethanol. hCSCs were treated with three
concentrations of PEITC (2.5, 5, and10 µM). After 24 and 48 hours of incubation, 20 µl
of CellTiter reagent was added directly to the cell-culture wells and incubated for 1 hour
at 37 °C, followed by cell viability assessment using the CellTiter 96 AQueous One
Solution Cell Proliferation Assay kit (Promega, Madison, WI), containing [3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt; MTS]. The manufacturer’s instructions were followed, and treatments were
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compared with vehicle control (DMSO-treated cells) at 490 nm in a BioTek Synergy H4
multimode plate reader (BioTek, Winooski, VT).

Immunoblotting
hCSCs (1×106) were seeded in each well of a 6-well plate and incubated
overnight at 37°C in a 5% CO2 incubator. Old culture medium was replenished by culture
medium containing 1.25, 2.5, 5 or10-µM concentrations of PEITC for 3 hours. Cell
harvesting and immunoblotting were carried out as we previously reported [59]. Briefly,
cells were lysed in ice-cold RIPA buffer containing 150 mM NaCl, 50 mM Tris (pH 8.0),
10% glycerol, 1% Nonidet P-40 (NP-40), and 0.4 mM EDTA, followed by a brief
vortexing and rotation for 30 minutes at 4 °C. Equal amounts (v/v) of cell lysates were
separated by SDS-PAGE through a 12% separating gel, transferred to nitrocellulose
membranes blocked with 5% non-fat dry milk, and double-probed overnight at 4 °C with
mouse anti-human Sp1 (1:1000 v/v, Millipore, Billerica, MA) and rabbit anti-human βactin (1:5000 v/v, Millipore, Billerica, MA) antibodies. Blots were then washed in PBS
and further incubated with secondary antibodies, goat anti-rabbit horseradish peroxidase
(1:5000 v/v, Millipore, Billerica, MA), for 1 hour at room temperature. Finally, after
rinsing in Tween20 (0.1% in PBS), blots were incubated for 5 min in enhanced
chemiluminescent substrate for horseradish peroxidase (SuperSignal™ West Femto,
Thermo Fisher Scientific, Waltham, MA) and imaged with a ChemiDoc XRS+ Imaging
System (BioRad, Hercules, CA), followed by a mean fluorescence intensity analysis of
Sp1 levels.
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Tumorigenicity study in mice
Animal studies were carried out in accordance with the guidelines of the
Institutional Animal Care and Use Committee (IACUC), South Dakota State University
(IACUC approval #12-087A). Sixteen female non-obese diabetic, severe combined
immunodeficient (NOD/SCID, NOD.CB17-Prkdcscid/J) mice (Jackson Laboratories, Bar
Harbor, ME), 5 weeks old, were randomly grouped into four groups (four mice per
group) in specific pathogen-free (SPF) housing at a constant temperature of 24–26 °C
with a 12-h:12-h light/dark cycle. All mice were allowed to acclimatize for 1 week and
were provided with sterile food and water ad libitum. HeLa and hCSCs were cultured,
trypsinized, washed, pre-treated with 10 µM PEITC where indicated, and resuspended in
PBS at the concentration of 1×107 cells/ml before injecting into the mice. Each mouse
was subcutaneously injected at both flank regions with one injection of PBS (100 µl,
control group), HeLa (1×106), hCSCs (1×106), or hCSCs pretreated with 10 µM PEITC
(1×106). The cell number in each injection was consistent with the study previously
carried out by Gu et al. [246]. All mice were routinely monitored for tumor formation,
weight loss, pain, and distress. The mice were euthanatized with CO2 asphyxiation 28
days post-treatment. The average tumor number per injection was calculated in each
group.

Statistical analysis
Statistical analyses were carried out using Sigma Plot software (Systat Software,
Inc., San Jose, CA). Analysis of variance (ANOVA) followed by a Dunnett’s post hoc
test was used to compare multiple means. Statistical significance between the groups was
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assessed by Student’s t test when compared two groups receiving similar treatments. Data
were expressed as means ± SEM. Experiments were repeated at least three times. The
significance of differences between means is represented by asterisks: *p≤0.05,
**p≤0.01, ***p≤0.001.

5.4. Results
Sphere culture enriches ALDHhighCD44high hCSCs
Since others and we have shown that sphere culture enriches the population of
sphere-forming CSC-like cells in HeLa cervical cancer cell line [61, 246], we further
seek to quantify this enrichment in HeLa cells through a well-established cervical CSC
marker, ALDH1 [55]. In order to use Aldefluor assay we first optimized the proper
concentration of hCSCs and found that 2 x 105 cells/ml produced the optimum signal
intensity when compared to 5 x 105 and 1 x 106 cells/ml (data not shown). After growing
the cells in serum free sphere-culture medium, 25.40 % of ALDHhi in HeLa cells at day 0
significantly enriched (p<0.001) to 57.75 % at day 10 (Figure 5.1). On the contrary, HeLa
cells grown for 10 days in complete growth medium with 10% fetal bovine serum (FBS)
did not allow sphere formation and hence did not change ALDHhi cells (data not shown).
These ALDHhi hCSCs were also confirmed to be CD44hi cells, further validating the
sphere-culture mediated enrichment of hCSCs.

PEITC inhibits the activity of ALDH1 in both HeLa cells and hCSCs
PEITC inhibits ALDH2 in liver [244]. Since NCBI blast revealed that ALDH1
and ALDH2 share 68% of amino acid sequences, we hypothesized that PEITC could also
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inhibit ALDH1in CSCs. As expected, PEITC attenuated ALDHhi cells in HeLa cells
when compared to DMSO control (15.82% vs 22.41%), using DEAB as a negative
control for Aldefluor reagent Figure 5.2a). Similarly, PEITC (10 µM) also attenuated
ALDH enrichment in hCSCs when compared to DMSO control (40.96% vs 56.71%),
using disulfiram as a positive control (Figure 5.2c, 5.2d). We observed that both PEITC
and disulfiram had similar ALDH1 inhibiting effects on hCSCs. Further, we sought to
understand the dose response (1.25 – 10 µM) of PEITC on inhibiting ALDH1 in hCSCS.
1.25 µM PEITC inhibited ALDHhi cells by 20% (p<0.01), where as 5 and 10 µM PEITC
inhibited ALDHhi cells by around 40% and 65% (p<0.001), respectively (Figure 2e).
Taken together, PEITC inhibited ALDH1, further attenuating the population of hCSCs.

PEITC induces ROS in hCSCs
Being an electrophilic in nature PEITC tends to covalently interact with
nucleophilic GSH, leading to ROS-induction in cells [240]. Since CSCs possess high
level of GSH as defensive machinery, we hypothesized that PEITC could selectively
induce more ROS in hCSCs. DCFDA ROS assay revealed that PEITC (10 µM) increased
ROS production by 1.4 fold higher than that of DMSO control using H2O2 (50 µM) as a
positive control (Figure 5.3). Interestingly, when the PEITC-treated cells were
replenished with GSH (25 nM), the cells came back to the normal redox status, further
supporting the ROS induction by PEITC in hCSCs.
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PEITC inhibits proliferation of hCSCs and induces apoptosis
Sphere formation assay showed that the sphere-forming capacity of hCSCs was
inhibited by PEITC in a dose dependent manner (Figure 5.4a). Moreover, the MTS
cytotoxicity assay revealed PEITC significantly reduced the viability of hCSCs by around
20% and 70% when treated for 24 hr and 48 hr, respectively with a concentration of 5
µM (p<0.05) and 10 µM (p< 0.001) (Figure 5.4b). Propidium iodide and Annexin V
assay revealed that PEITC (10 µM) significantly increased (p<0.01) the early apoptotic
cells when compared with DMSO control (6.42% vs 3.89%) (Figure 5.4c). Together,
PEITC showed its pro-apoptotic and anti-proliferative properties in hCSCs.

PEITC inhibits Sp1 and P-gp proteins in hCSCs
In our previous study [61], when compared to parental HeLa cells hCSCs caused
more efflux of Hoechst 33342 dye, which is a substrate of multi-drug transporter P-gp
protein [247]. Hence, we hypothesized that PEITC might inhibit P-gp protein in hCSCs.
Flow cytometric analyses revealed that PEITC (10 µM) inhibited P-gp positive hCSCs
when compared to DMSO control (4.5% vs 9%) (Figure 5.5c, 5.5d). Since
Sp1transcription factor is involved in the binding of promoter region of MDR1 (P-gp)
gene, we sought to understand if PEITC could inhibit Sp1 protein. Western blot followed
by mean fluorescence intensity analyses showed that Sp1 protein was inhibited by PEITC
in a dose dependent manner, using Sp1 inhibitor mithramycin as a positive control
(Figure 5.5a, 5.5b). To confirm the correct band of Sp1 protein, we used HeLa nuclear
extract as a positive control in a separate blot (data not shown).
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PEITC inhibits CSCs in vivo and prevents metastasis in mice
In order to confirm the higher tumorigenic potential of hCSCs in vivo and its
attenuation by PEITC, we carried out a xenotransplant NOD-SCID mouse model with
two treatment groups and a negative control group. Normal body weight and activity
among all the groups confirmed that there was no alteration in food intake of the mice
due to tumor development (data not shown). Equal number of hCSCs (1x106) with 10 µM
PEITC pre-treatment (hCSC+PEITC) developed lower tumor load when compared to
without PEITC pretreatment group (hCSC) (Table 5.1). Interestingly, mice in hCSC
group started forming the tumors in only about 2 weeks. Taken together, hCSCs initiated
tumor formation and its tumorigenicity was attenuated by PEITC pre-treatment prior to
xenotransplant.

5.5. Discussion
Absence of rigorous screening program has made the cervical cancer the secondmost-fatal cancer in women worldwide, especially more prevalent in developing nations
[248]. Since others and we have shown that PEITC can induce the death receptormediated extrinsic apoptosis pathway in human cervical cancer cell line and cervical
cancer stem cells [61, 249], this study highlighted the intrinsic apoptotic pathway
involving ROS and mitochondrial oxidative stress in cervical CSCs. Using aldefluor
assay on hCSCs enriched through cervical HeLa sphere culture, here we showed for the
first time that PEITC inhibited ALDH1, a marker of cervical cancer stem cells and
induced ROS-mediated apoptosis in hCSCs through inhibition of Sp1 transcription factor.
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20 years ago, Lindros et al. described PEITC as an inhibitor of mitochondrial
ALDH in liver in the context of alcohol administration, with a similar effect as that of a
known ALDH inhibitor, disulfiram [244]. This is due to accumulation of ethanolproduced toxic acetaldehyde [250], which cannot be converted into acetic acid due to
lack of ALDH2 enzyme. Interestingly, this old concept did not get much attention until
ALDH was later proposed as a novel CSC marker in a breast cancer [52]. Since ALDH is
functionally associated with redox balance in CSCs, an inhibition of ALDH1 by PEITC
could induce ROS in CSCs (Figure 5.3). Despite the paradoxical role of PEITC, an
antioxidant in lower doses and pro-oxidant in higher doses in normal healthy cells, its
pro-oxidant role in cancer cells is well studied [243]. Intriguingly, another ALDH2
inhibitor, disulfiram, has been associated with induction of ROS and inhibition of a CSC
marker ALDH1 [251]. Moreover, sulforaphane, a closely related isothiocyanate to
PEITC, has been already shown to inhibit ALDH1in breast CSCs [252], further
supporting the CSC-targeted chemotherapeutics potential of PEITC.
Previous study that showed PEITC modulate drug efflux transporter proteins like
P-gp [253] in cisplatin-resistant gastric cancer cell line also supports our observation that
PEITC ainhibits P-gp in CSCs (Figure 5.5). This could be one of the explanations for
PEITC-associated sensitization of other conventional drugs, which are mostly effluxed
through P-gp transporter [254], which is mediated through multidrug resistance gene
(MDR1). Therefore, PEITC, either alone or in combination, may be useful as the
therapeutic strategy for overcoming multi-drug resistance.
Interestingly, promoter of the MDRl gene gets activated with specificity protein
(Sp1) [235], which may link to its significantly higher expression in colon CSCs than
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parent cancer cells [255]. Mechanistically, higher expression of Sp1 and related Sp
proteins in cancer is governed, in part, by miroRNA-regulated transcriptional repressors
like ZBTB proteins, which directly compete with Sp proteins to bind onto GC-rich
promoter regions. In this context, recently it has been shown that PEITC induced
glutathione (GSH)-dependent ROS in pancreatic cancer cells resulting a downregulation
of miR-27a and miR-20a/miR-17-5p, which induced ZBTB10 and ZBTB4, respectively,
and in turn inhibited Sp proteins [256]. Moreover, the Sp1 transcription factor is a target
of histone acetylation associated with histone deacetylase (HDACs) inhibitors [236].
Since PEITC is also an HDAC inhibitor in prostrate cancer cells [257], Sp1 inhibition
could be an important epigenetic mechanism of action for induced apoptosis due to
PEITC and other ROS-inducing anticancer agents [256], further validating our findings in
CSC-specific context that merit further study.
In this study PEITC also induced ROS in 3 hr, and the effect was attenuated when
the cells were replete with GSH (Figure 5.3). Since cellular redox homeostasis is
dependent on GSH and thiol-regulating glutaredoxin enzyme system [258], PEITC
utilizes this redox machinery to bind and deplete GSH, leading to ROS-induced cell
apoptosis [243, 256]. Strikingly, CSCs that have higher levels of GSH are relatively more
sensitive to PEITC, which may also explain its selectivity toward CSCs compared with
cancer cells and normal cells. 1.5–10-µM final concentrations of PEITC used in this
study are achievable following oral administration in human [259] and have been already
used in our prior studies to induce apoptosis in the SW480 colon cancer cell line [59] and
cervical cancer stem-like cells [61]. Hence, targeting CSCs with a natural compound

124
PEITC have significant implications on minimizing tumor recurrence and associated
health care costs.

5.6. Conclusion
This novel study demonstrated that PEITC inhibited CSC marker ALDH1 and
induced ROS-mediated apoptosis, inhibiting the proliferation and sphere-formation
potential of hCSCs, which correlated with the less tumor counts in vivo. Since PEITC
also suppressed Sp1 transcription factor and multi-drug resistance protein P-gp, this study
provides a substantial proof-of-concept that PEITC targets cancer stem cells using HeLa
CSCs as a model. Hence, PEITC commonly obtained from cruciferous vegetables can
effectively target chemo-and-radiotherapy-resistant CSCs, fighting against the cancer
relapse and associated healthcare-cost burden.

5.7. Future Directions
1. To sort the ALDHhi cells using FACS and carryout the in vitro experiment,
2. To inject CSCs in multiple concentrations to see the concomitant inhibitory
effects PEITC concentrations in tumor inhibition in NOD/SCID mice
3. To identify the active binding site of ALDH1 enzyme and to establish the role of
cysteine in activity of PEITC
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Figures and Legends

Figure 5.1. Sphere culture enriches ALDHhiCD44hi hCSCs population from parental
HeLa cells
a) Representative FACS dot plots showing enrichment of ALDHhi cancer stem cells from
day 0 to day 10 due to sphere culture in low anchorage dishes. The ALDHhi gated cells
were mostly CD44 positive. b) Bar graphs representing ALDH enrichment in HeLa (Day
0) and hCSCs (Day 10). All data represent means ± SEM, ***p ≤ 0.001
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Figure 5.2. PEITC inhibits ALDH activity in HeLa and hCSC
a) Representative FACS dot plots showing PEITC inhibits ALDH activity in HeLa cells
(a) and hCSCs (c). b) Bar graphs showing the reduction of ALDH high cells in HeLa (b)
hCSC, hCSC + PEITC, and hCSC + Disulfiram treatments, using Disulfiram as a positive
control (d). e) Bar diagrams showing inhibition of ALDH high hCSCs by PEITC in a
dose dependent manner. All data represent means ± SEM, *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001.
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Figure 5.3. PEITC induces ROS in hCSCs
a) Representative FACS histograms showing PEITC induces ROS in hCSCs with H2O2
as a positive control. b) Overlay image of histograms showing ROS induced by PEITC
can be replenished by exogenous glutathione c) Bar diagram showing the ROS induction
by PEITC in hCSCs.
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Figure 5.4: PEITC inhibits proliferation of hCSCs and induces apoptosis
a) Representative photomicrographs showing attenuation of hCSCs sphere formation
(day 7) by PEITC in a concentration-dependent manner (400-µm scale). b) Bar graphs
showing concentration-dependent effects of PEITC on the viability of hCSCs after 24 hr
treatment (n=6). The dotted line represents the baseline cell viability for DMSO, which
served as a control to determine statistical significance. c) Bar graphs showing the
percentage of apoptotic cells obtained from propidium iodide and Annexin V assay. All
data represent means ± SEM, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Dr. Yi Liu and Dr. Dan
Wang helped with this figure.
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Figure 5.5. PEITC inhibits transcriptional factor Sp1 and multidrug resistance
protein ABCB1 in hCSC
a) Western blots showing PEITC inhibits Sp1 in a dose dependent manner and their
corresponding bar graphs with relative Sp1 expression (b) c) FACS histograms showing
PEITC inhibits multi-drug resistance protein P-Gp (ABCB1) D) Bar graphs showing
PEITC inhibits multi-drug resistance protein P-Gp (ABCB1). All data represent
means ± SEM, *p ≤ 0.05.
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Table 5.1. Number of tumors in treatment groups in NOD/SCID mouse model

HeLa

Tumors at
week 2
0/8

Tumors at
week 4
3/8

hCSC

1/8

4/8

hCSC + PEITC

0/8

1/8

Cells Injected

NOD/SCID: Non-obese diabetic/severe combined immunodeficient
hCSC: HeLa cancer stem cell
PEITC: Phenethyl isothiocyanate
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CONCLUSIONS
This dissertation study provides the evidence that dietary fiber RS4
supplementation selectively changes the gut microbial and metabolite environment as
well as associated host metabolic functions in a free living Caucasian cohort with signs of
MetS. These results backed-up by in vivo study using a suitable mouse model of MetS
further supports the perceived anti-inflammatory role of bacterial metabolites,
particularly butyrate, in attenuating intestinal inflammation epigenetically. This study is
also the first to further explain the role of maternal high fat diet on heart tissue-specific
differential histone modifications in the rat offspring born to obese and/or diabetic
pregnancy, highlighting the fuel-mediated cardiac dysfunction in offspring that increase
the adult-onset of CVDs. Further, PEITC commonly obtained from cruciferous
vegetables effectively target chemo-and-radiotherapy-resistant cancer stem cells, fighting
against the cancer relapse and associated healthcare-cost burden.
Further characterization of prebiotic functional fibers-associated epigenetic
alterations may provide effective strategies to mitigate the low-grade inflammation in the
context of intestinal as well as extra-intestinal diseases associated with dysbiosis. In
addition, identification of the reversible epigenetic landscape in utero and its association
to risks for adult-onset of chronic CVDs provides an effective strategy for novel cardiometabolic health management in next generation and future generations. Hence, this
study enhances the knowledgebase of nutritional therapies with important implications
for dietary guidelines to decrease the high fat with an increase in fiber and vegetables
consumption in our daily meal for all individuals in all life stages.
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